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1. INTRODUCTION  
 
          The liver plays a role of vital functions in the performance, maintenance and 
regulating homeostasis of the body. It is involved with almost all the biochemical 
pathways to growth, fight against disease, nutrient supply and energy provision. 
Therefore, carrying of a healthy liver is important for the overall wellbeing of an 
individual.
1,2
 
 
          Liver diseases are the most serious illness and major health problem around the 
world. The liver toxicity mainly caused by toxic chemicals like excess consumption of 
alcohol, high doses of paracetamol, toxic industrial chemicals, aflatoxins, carbon 
tetrachloride, water pollutants, chemotherapeutic agents, peroxidised oil, etc
3
.
 
This 
increases the risk of liver diseases like Hepatitis, Alcoholic liver disease, Hereditary 
diseases, Cirrhosis, Fatty liver disease, Non-alcoholic fatty liver disease etc. The 
important health complication of liver disease is rise along with the increasing in size of 
population. It is a major cause of mortality increasing every year and the fifth big killer 
in countries such as Wales and England.
4  
 
          According to the World Health Organization (WHO) 21.96% of death occurred 
due to liver disease in India
3
. India has reached the 61
st
 position in the world in liver 
disease. As the number of annual liver cancer and cirrhosis deaths increased by 1.25 to 
1.75 million from 1990 to 2010. In 2010, hepatitis B virus was associated with 45% of 
liver cancer and 30% of cirrhosis deaths, whereas hepatitis C and alcohol each caused 
about 25% of liver cancer and cirrhosis. 
  
          Cirrhosis is well recognized and the main cause of hepatocellular carcinoma 
(HCC), which has an annual global incidence over half a million, and a 5 year survival of 
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10%, the incidence of this cancer has been steadily rising at an alarming rate, making 
HCC the 4th most common cancer in men and the 7th most common cancer in women in 
recent estimates. It is likely to contribute approximately 5.6% of all human cancers with 
a predicted increase in burden through 2020. Almost 85% of HCC occurs in the 
developing world. Hepatitis C virus related HCC is the fastest rising cause of cancer 
related deaths in the developed countries. It accounts for 70% to 85% of primary liver 
cancers. With the rising incidence of Nonalcoholic Steatohepatitis (NASH) and 
metabolic syndrome, these are also becoming a major concern. 
 
          Cirrhosis affects hundred to millions of patients worldwide. The overall burden of 
liver disease in the United States the vast majority of which is due to chronic disease 
with fibrosis-continues to expand, exacting a raising economic and social cost. Indeed, in 
the United States, cirrhosis is the most common non-neoplastic cause of death among 
hepatobiliary and digestive accounting approximately 30,000 deaths per year. Notably, 
hepatocellular carcinoma is the most rapidly increasing neoplasm in the United States 
and Western Europe. 
 
          Liver cancer was recognized as the 4th most common cancer in males and 
accounted for 37% of all infection-related cancers in females in a recent study from 
India.
 
 Data from 1992–2002 showed that combined liver and intrahepatic bile duct 
cancer ranked 12th in males and 18th in females with rates of 8.6%and 3.3% per 100,000 
persons, respectively. The mortality rates for liver and intrahepatic bile duct cancers 
were still higher, ranking 10th for men and 13th for women.
5
 
 
          Statistics obtained from birth and death registration department of Pune Municipal 
Corporation, showed that an average of 35-40 people die every month of liver related 
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problems. Statistics revealed that nearly 2 lakh people in India die of terminal liver 
disease.
4,5 
 
     
      In spite of the very great advances made in modern systems of medicine; no 
effective hepatoprotective medicine is available. Medicinal plants are great economic 
importance in the Indian subcontinent. The documentation of traditional knowledge 
especially on the medicinal use of plants in the history has provided many important 
drugs of the modern day. Even today, this area holds much more hidden treasure as 
almost 80% of human population in developing countries is dependent on plant resources 
for healthcare. Herbal medicines offer conventional treatments, provide safe and well-
tolerated remedies for chronic illness which typically resulted from the combinations of 
secondary plant metabolites that are synthesized and deposited in specific parts or in all 
parts of the plant. Since, many synthetic drugs cause various side effect, drugs 
synthesized from the higher plants continue to occupy an important role in modern 
medicine and introduction of new therapeutic agents.
4 
 
1.1 Advantages of herbal medicine:    
 Herbal medicines have long history of use and better patient tolerance as well as 
acceptance. 
 Medicinal plants have a renewable source which is our only hope for sustainable 
supplies of cheaper medicines for the world growing population. 
 Availability of medicinal plants is not a problem especially in developing 
countries like India having rich agro-climatic, cultural and ethnic biodiversity. 
 Prolonged and apparently uneventful use of herbal medicines may offer 
testimony of their safety and efficacy.   
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          Scientific studies available on medicinal plants indicate that promising 
phytochemicals can be cure health problems. For example, the Silybum marianum 
(silymarin), Citrus paradise, Vitis vinifea L., Opuntia ficus-indica, Matricaria 
chamomilla have been employed for their hepatoprotective properties.
6
  
 
          Modern pharmaceuticals still contains 25% drugs derived from plants. Medicinal 
plants have various effects on living systems. Some are sedatives, analgesics, 
antipyretics, cardioprotectives, antibacterial, antiviral and antiprotozoal
5
. Plant drugs are 
known to play a vital role in the management of liver diseases. There are great in number 
of plants claimed to have hepatoprotective activities.
3
  
 
          Liver protective plants contain a variety of chemical constituents like coumarins, 
phenols, glycosides, monoterpenes, xanthenes and alkaloids. These findings provide 
great chances and flexibility in helping researchers identify compounds with good 
hepatoprotective potential.
6  
 
 
          So, the development of plant based hepatoprotective drugs has been given 
importance in the global market. There are many plants which have not been subjected 
through scientific evaluation. Erythrina indica Lam leaves have been studied and they 
are known to possess hepatoprotective activity. The leaves contain rich phytoconstituents 
like flavonoids, isoflavonoids, coumarins, phenols. The presence of flavonoids has been 
reported as the reason for their hepatoprotective activity. 
 
          The stem bark not been so far subjected to hepatoprotective activity screening. The 
Erythrina indica Lam belongs to the family fabaceae. The stem bark of Erythrina indica 
Lam is also rich in flavonoids and iso-flavonoids
7
. Hence the present study was carried 
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out to explore the hepatoprotective efficacy of stem bark of Erythrina indica Lam against 
CCl4 induced hepatotoxicity in rat’s model.
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2. AIM AND OBJECTIVE 
 
          The literature review indicated that plant of Erythrina indica generally rich sources 
of antioxidants and hence may be considered to be good potential for hepatoprotective 
activity. From the literature review it is clear that no scientific work has so far been 
carried out on the stem bark of Erythrina indica Lam for hepatoprotective activity. 
 
          The aim and objective of the study is 
 
 Evaluation of the phytochemical screening of various extracts of stem bark of 
Erythrina indica Lam. 
 
 Evaluation of the hepatoprotective activity of various extracts of stem bark of 
Erythrina indica in Carbon tetrachloride induced hepatotoxicity in rats. Biochemical 
estimations are,   
 Estimation of Aspartate amino transferase (AST)   
 Estimation of Alanine aminotransferase (ALT) 
 Estimation of Alkaline phosphate (ALP)       
 Estimation of Total bilirubin (TB) 
 Estimation of Total protein content (TP) 
 Estimation of serum Albumin (ALB) 
 
 Assessment of in vivo antioxidant property of various extracts of stem bark of 
Erythrina indica Lam.  
 Super oxide dismutase (SOD) 
 Lipid peroxidation (LP) 
 Glutathione peroxidase (GPx) 
 Catalase (CAT) 
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3. REVIEW OF LITERATURE 
 
3.1 DISEASE PROFILE 
          The liver is a dynamic organ characterized by several unique properties, including 
self-renewal, that permit its daily exposure to ingested nutrients, gut-derived endobiotics, 
and xenobiotic metabolism without adverse consequences. The unique position of the 
liver also confers vulnerability to wide variety of insults and injury. These are 
characterized by cell death, which can target any cell type in the liver. Hepatocytes, the 
most abundant cell type, are commonly affected in both acute and chronic liver diseases. 
Hepatic inflammation facilitates, accelerates, and augments liver injury
8
. Liver 
disease (also called hepatic disease) is a type of damage to liver or disease of the liver
9
. 
There are more hundred kinds of liver diseases; some of the most common ones are,  
 
Fibrosis and cirrhosis
10,11
  
          Hepatic fibrosis refers to the accumulation of extracellular matrix, or scar tissue, in 
response to acute or chronic liver injury. The injury ultimately leads to the clinical-
pathologic syndrome known as cirrhosis. From a histologic standpoint, cirrhosis can be 
considered the end stage consequence of fibrogenesis occurring in the hepatic 
parenchyma, resulting in nodules formation and blood flow and the clinical sequelae 
typical of cirrhosis. Both fibrosis and cirrhosis are the consequence of a sustained wound 
healing response to chronic liver injury from a range of causes including viral, 
autoimmune, drug-induced, cholestatic, and metabolic diseases. Nearly 40% of patients 
with histologic cirrhosis are asymptomatic and may remain so for long periods of time. 
However, once complications (e.g., ascites, variceal hemorrhage encephalopathy) 
develop, progressive deterioration leading to death or liver transplantation is typical. In 
Review of Literature 
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such patients there is 5-year mortality, with approximately 70% of these deaths directly 
attributable to liver diseases. In asymptomatic individuals, cirrhosis may be first 
suggested during routine examination, although histological analysis may be required to 
establish the diagnosis. 
 
Hepatitis 
          Hepatitis refers to an inflammatory condition of the liver. It is commonly caused 
by a viral infection, but there are other possible causes of hepatitis. These include 
autoimmune hepatitis and it occurs as a secondary result of medications, drugs, toxins 
and alcohol. Autoimmune hepatitis is a disease that occurs when your body makes 
antibodies against your liver tissue. 
          Hepatitis A, B, and D are preventable with immunization. Medications may be 
used to treat chronic cases of viral hepatitis
2
.There is no specific treatment for NASH; 
however, a healthy lifestyle, including physical activity, a healthy diet and weight loss, is 
important. It may be treated with medications to suppress the immune system. A liver 
transplant may also be an option in certain cases.  
Alcoholic liver diseases  
          Alcoholic liver disease is a term encompasses the liver manifestations of alcohol 
over consumption, including fatty liver, alcoholic hepatitis and chronic hepatitis with 
liver fibrosis or cirrhosis. 
          It is the major cause of liver disease in Western countries. Although steatosis (fatty 
liver) will develop in any individual who consumes a large quantity of alcoholic 
beverages over a long period of time, this process is transient and reversible. Of all 
chronic heavy drinkers, only 15–20% develops hepatitis or cirrhosis, which can occur 
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concomitantly or in succession. The mechanism behind this is not completely 
understood. 80% of alcohol passes through the liver to be detoxified. Chronic 
consumption of alcohol results in the secretion of pro-inflammatory cytokines (TNF-
alpha, Interleukin 6 and Interleukin 8 [IL8] ), oxidative stress, lipid peroxidation, 
acetaldehyde toxicity and decreasing antioxidant enzymes levels. These factors 
cause inflammation, apoptosis and eventually fibrosis of liver cells.  
Fatty liver disease  
          Fatty liver is a reversible condition where in large vacuoles of triglyceride fat 
accumulate in liver cells via the process of steatosis (i.e., abnormal retention 
of lipids within a cell). Despite having multiple causes, fatty liver can be considered a 
single disease that occurs worldwide in those with excessive alcohol intake and obese 
(with or without effects of insulin resistance). The condition is also associated with other 
diseases that influence fat metabolism
2
. When this process of fat metabolism is 
disrupted, the fat can accumulate in the liver in excessive amounts, thus resulting in a 
fatty liver. It is difficult to distinguish alcoholic FLD from nonalcoholic FLD, and both 
show microvesicular and macrovesicular fatty changes at different stages. 
          Accumulation of fat may also be accompanied by a progressive inflammation of 
the liver (hepatitis), called steatohepatitis. By considering the contribution by alcohol, 
fatty liver may be termed alcoholic steatosis or nonalcoholic fatty liver disease(NAFLD), 
and the more severe forms as alcoholic steatohepatitis (part of alcoholic liver disease) 
and non-alcoholic steatohepatitis (NASH). 
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Nonalcoholic fatty liver disease 
          Non-alcoholic fatty liver disease (NAFLD) is one of the types of fatty liver which 
occurs when fat is deposited (steatosis) in the liver due to causes other than excessive 
alcohol use. NAFLD is the most common liver disorder in developed countries. NAFLD 
is related to insulin resistance and the metabolic syndrome and may respond to 
treatments originally developed for other insulin-resistant states (e.g. diabetes mellitus 
type 2) such as weight loss, metformin, and thiazolidinediones. Up to 80% 
of obese people have the disease. Non-alcoholic steatohepatitis (NASH) is the most 
extreme form of NAFLD, and is regarded as a major cause of cirrhosis of the liver of 
unknown cause.   
Hereditary disease 
 Hereditary diseases that cause damage to the liver include hemochromatosis, 
involving accumulation of iron in the body and Wilson’s disease. Liver damage is also a 
clinical feature of alpha 1- antitrypsin deficiency and glycogen storage disease type II. 
Gilbert’s syndrome 
          Gilbert's syndrome (GS) is a common genetic liver disorder. It produces elevated 
levels of unconjugated bilirubin in the bloodstream (hyperbilirubinemia), but this 
normally has no serious consequences, although mild jaundice may appear under 
conditions of exertion or stress. 
          The cause of this hyperbilirubinemia is the reduced activity of the enzyme 
glucuronyltransferase, which conjugates bilirubin and a few other lipophilic molecules. 
Conjugation renders the bilirubin water-soluble, after which it is excreted in bile into the 
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duodenum. There are a number of variants of the gene for the enzyme, so the genetic 
basis of the condition is complex. 
Autoimmune disorder 
          Sometimes the immune system may begin to attack the liver or bile ducts causing 
inflammation and scaring which leads to a progressive form of liver disease. Examples 
of liver disease believed to be caused by the immune system are primary biliary cirrhosis 
(PSC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis. 
Fascioliasis 
          Fasciolosis (also known as fascioliasis, distomatosis and liver rot) is a parasitic 
worm infection caused by the common liver fluke Fasciola hepatica as well as 
by Fasciola gigantica. The disease is a plant-borne trematode zoonosis and is classified 
as a neglected tropical disease (NTD). It affects humans, but its main host is ruminants 
such as cattle and sheep. The disease progresses through four distinct phases; an initial 
incubation phase of between a few days up to three months with little or no symptoms; 
an invasive or acute phase which may manifest with: fever, malaise, abdominal pain, 
gastrointestinal symptoms, urticaria, anemia, jaundice and respiratory symptoms. The 
disease later progresses to a latent phase with less symptoms and ultimately into a 
chronic or obstructive phase months to years later.
1,5
 In the chronic state the disease 
causes inflammation of the bile ducts, gall bladder and may cause gall stones as well 
as fibrosis. While chronic inflammation is connected to increased cancer rates; it is 
unclear whether Fascioliasis is associated with increased cancer risk. 
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Causes of liver damage 
Chemical induced liver damage: carbon tetrachloride, alcohol consumption, 
aflatoxins, 1, 1, 2, 2-tetrachloroethane, carbon tetrabromide, dimethyl formamide, 
ethylene dichloride.  
Mechanism of Chemical induced hepatotoxicity
10 
          Most of the chemicals produce hepatotoxicity by oxidative stress mechanism. 
Oxidative stress is an imbalance between oxidants and anti-oxidants in favor of the 
oxidants, leading to a disruption of redox signaling and control and/or molecular 
damage. A key mechanism involves reactive oxygen species (ROS), reactive 
nitrogen species (RNS), and a range of free radicals generated by bioactivation of 
xenobiotics. All of the classes of cellular macromolecules can be the target of 
oxidant-induced liver injury. Proteins are most often considered the critical targets in 
acute necrosis, but oxidants also genobiotic. Non radical oxidants, such as hydrogen 
peroxide and lipid hydroperoxides, are quantitatively most important under most 
conditions; however, free radicals can also be important in mediating hepatotoxicity. 
Free radicals can be generated in the liver in several ways. CYP enzyme generate 
radicals from xenobiotics by different mechanisms: 1-electron oxidation to form a 
cation radical (R          ●R+ + e-); 1-electon oxidation to form a cation radical           
(R + e
-   
      ●R-); or hemolytic bond scission to yield a neutral radical (R-        ●R + 
●R). Hepatotoxicants of occupational/environmental (e.g.; CCl4) as well as of 
clinical importance (e.g. halothane) are bioactivated in liver to free radical species. 
CCl4 toxicity provides a useful model and is representative of a large number of 
halogenated hydrocarbons that can be similarly activated.                                                          
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Figure.1: Hepatic metabolism and oxygen-dependent effects of carbon tetrachloride (CCl4) 
 
 
      
      Low oxygen                                                      High oxygen 
 
 
 
 
 
 
 
 
 
 
           
          CCl4 is a prototypical hepatotoxin that causes centrilobular necrosis and 
associated fatty liver. Caspase-3 is activated and release in to the plasma with a time 
course suggesting initial activation of apoptosis followed by secondary necrosis. A 
primary event in the pathogenesis is the reductive dehalogenation of CCl4 to the 
trichloromethyl free radical (●CCl3) by hepatic mixed function oxidases (fig.1). The 
free radical ●CCl3 can initiate lipid peroxidation, and in the presence of oxygen it 
forms the more reactive trichloromethylperoxy free radical (CCl3OO●), which also 
decomposes to phosgene (CC2O). The lipid peroxidation in the liver associated with 
CCl4 has been viewed as a critical event because it occurs early and is associated with 
reductions of enzyme activities and inactivation of the Ca
+ 
concentration establishes 
conditions for activation of the mitochondrial permeability transition, with associated 
cytochrome c release and caspase activation. In addition to free radicals of the parent 
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compound, other reactive oxygen and reactive nitrogen species are often involved in 
hepatotoxicity. 
     Alcohol abuse 
Drug induced: more than 900 drugs have been implicated in causing liver injury and 
it is the most common reason for a drug to be withdrawn from the market. Drug 
induced liver injury is responsible for 5% of hospitalized persons and 50% of all 
acute liver failures. Some of them are Acetaminophen over dose, Amiodarone, 
Ketoconazole, Rifampicin. 
Virus induced: Hepatitis A, B, C, D and E. 
Other causes;   Non-alcoholic fatty liver, malnutrition, extra hepatic infections, 
ingestion of poisonous wild mushrooms and haemochromatosis. 
Pathophysiology of liver damage
12 
          Hepatocytes make up 70-80% of the cytoplasmic mass of the liver. These cells are 
involved in protein synthesis, protein storage and transformation of carbohydrates, 
synthesis of cholesterol, bile salts and phospholipids, and detoxification, modification 
and excretion of exogenous and endogenous substances. The hepatocyte also initiates the 
formation and secretion of bile. Hepatocytes are able to synthesize hormones, like 
insulin-like-growth-factor IGF-1, thrombopoietin, and also erythropoietin. They also 
synthesize cytokines like interleukin (IL)-8 and respond to acute phase mediators like 
IL-6, with the synthesis of acute phase proteins like C-reactive protein (CRP) or serum 
amyloid A (SAA) and many others. The cells possess different intracellular defense 
proteins like heme-oxygenase-1 (HO-1). 
 
Review of Literature 
 
 
Institute of pharmacology, MMC  15 
  
          When however the defense mechanisms are not sufficient to withstand the 
damaging attacks cells start to synthesize chemokines (CXC-chemokines like: 
monokine-induced by gamma interferon (MIG), gamma-interferon-inducible protein (IP-
10), cytokine-induced neutrophil chemoattractant (KC) and macrophage inflammatory 
proteins (MIPs) (MIP-1, MIP-2, MIP-3), which are supposed to be responsible for 
attraction of inflammatory cells like granulocytes and mononuclear phagocytes and to 
activation of resident macrophages (Table-1, Fig. 1). In the attempt to eliminate the 
damaging toxin the defense response however leads to death of the stressed hepatocyte. 
 
          Hepatic stellate cells (HSC) and liver (myofibroblasts) have modulatory roles in 
inflammatory conditions, based on their capability of cytokine and chemokine 
production. The quiescent Stellate (Ito) cells (HSC) store vitamin A, but produce 
extracellular matrix and collagen when activated. They are located in the space of Disse 
between hepatocytes and endothelial cells. 
 
          Hepatic stellate cells might also play a role during liver inflammation. ICAM-1 
and VCAM-1 expression was present in HSC in vitro and in cells located in the 
sinusoidal/perisinusoidal area of normal liver. Growth factors, e.g., transforming growth 
factor-β1, down-regulated ICAM-1- and VCAM-1-coding mRNAs and stimulated N-
CAM expression of HSC. In contrast, inflammatory cytokines like tumor necrosis factor-
alpha reduced N-CAM-coding mRNAs, whereas induced of ICAM-1- and VCAM-1-
specific transcripts by several fold. HSC might be important during the onset of hepatic 
tissue injury by modulating the recruitment and migration of mononuclear cells within 
the perisinusoidal space of diseased livers. 
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          In addition, the secretion of several cytokines and chemokines was demonstrated 
in hepatic stellate cells including MCP-1, RANTES, IL-8 (Table 1, Fig.1). Sinusoids 
display a discontinuous, fenestrated endothelial cell lining. The sinusoidal "wall" does 
not possess a basement membrane and the endothelial cells are separated from the 
hepatocytes by the space of Disse which drains lymph into the portal tract lymphatics. 
Under normal conditions the hepatic sinusoidal endothelial cells express low levels of 
Rantes, macrophage-chemotactic-protein-1 (MCP-1), IL-8 and MIP-1α. These factors 
are involved in the routine leukocyte recirculation and immunological surveillance. 
During inflammation the chemokine expression profile of the normal hepatic 
endothelium changes. These changes are characterized by expression of high levels of 
MIP-1β, IP-10, MIG and IFN-gamma-inducible T cell alpha chemoattractant (ITAC) 
(Table 1, Fig. 2). Similarly to the chemokine profile the expression pattern of adhesion 
molecules also changes in the endothelial cells. It also expresses platelet endothelial cell 
adhesion molecule-1 (PECAM-1), vascular adhesion protein-1 (VAP-1) and intercellular 
cell adhesion molecule-2 (ICAM-2) under normal conditions of hepatic sinusoidal 
endothelial cells. During inflammation this expression pattern changes, characterized by 
the downregulation of PECAM-1, and upregulation of ICAM-1, of vascular cell adhesion 
molecule VCAM-1, and of P and E selectins. 
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Table – 1: Induction of chemical mediators in liver cells populations during liver 
inflammation 
 
Liver cells Mediators 
Hepatocytes IL-8, IP-10, MIG, MIP-1, MIP-2, MIP-3, KC 
Sinusoidal Endothelial Cells RANTES, MCP-1, IL-8, MIP-1α, MIP-1β; 
MIG, ITAC 
Kupffer Cells 
IL-1, IL-6, IL-10, IL-18, TNF-α, TGF-β, MIPs, 
IL-8, IP-109, KC/GRO, RANTES 
Hepatic Stellate Cells IL8, RANTES, MCP-1 
 
Fig.2: Sinusoidal structure in normal liver (A) and in liver inflammation (B) 
 
               The red blood cell is broken down by phagocytic action and the hemoglobin 
molecule is split. The globin chains are reutilized while the iron containing portion or 
heme is further broken down into iron which is reutilized and bilirubin, which is 
conjugated with glucuronic acid within hepatocytes and secreted into the bile. 
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          During liver injury induced by hepatotoxins or by Gram-negative bacterial 
lipopolysaccharide (LPS), or in association with sensitizers such as D-galactosamine, 
CCl4, dimethylnitrosamine, acetaminophen, alcohol, etc. the Kupffer cells get activated. 
Activation of Kupffer cells results in secretion of a large number of chemical mediators 
(cytokines: IL-1, IL-6, IL-8, TNF-α, etc. chemokines: C-X-C chemokines: MIP-2, IP-
109, KC/GRO; C-C chemokines: MIP-1α, MCP-1, RANTES), most of which can induce 
liver injury either by acting directly on the liver cells or via chemoattraction of 
extrahepatic cells (e.g. neutrophils and lymphocytes) (Table 1, Fig. 2). During 
inflammatory conditions the expression pattern of adhesion molecules is also changed in 
the Kupffer cells, similarly to the sinusoidal endothelial cells. The most characteristic 
change is the downregulation of PECAM-1 and the upregulation of ICAM-1 (Fig. 2). 
 
          Besides synthesis of IFN-γ upon triggering by the damaging noxae, the most 
important function of the NK cells is the destruction of virus-infected and malignant cells 
without previous activation. NK cells are able to migrate and transmigrate through 
epithels. NK cells can be activated by interleukin-2. The resulting cell population is 
known as lymphokine-activated killer cells (LAK). 
          The chemical mediators released by Kupffer cells and by hepatocytes attract 
extrahepatic cells to the liver. Neutrophils (PMN) are the characteristic cellular 
compound of the chemoattracted cells, and are involved in the acute inflammation 
(Fig.2). They are always present in the inflammatory infiltrate of chronic liver disease. 
However, neutrophil infiltration is most prominent in alcoholic hepatitis and 
extravasation and transmigration of neutrophils into the liver tissue are critical for 
neutrophil-induced injury and cytotoxicity. 
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          Up to now the role of T-lymphocytes in liver disease is still not clear. Previously a 
role was suggested of T-cells in liver injury by activating Kupffer cells to produce TNF-
α However there is also a considerable amount of data demonstrating that T-cell 
activation against liver antigens (after a transient cellular immune attack) induces 
tolerance and not immunity and a recent study suggests that at least natural killer T-cells 
might not concern in immune-mediated liver injury. Furthermore, other studies described 
the liver as graveyard for T-cells. 
 
Stages of liver damage;  
Fig. 3 
                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                       
       
                                               
 
 
 
 
               
 
 
STAGE 0 
Healthy liver 
STAGE 1 (INFLAMMATION) 
Beginning of liver damage 
STAGE 2 (SCAR FORMATION) 
Significant liver damage 
STAGE 3 
Severe liver damage 
(Cirrhosis) 
Review of Literature 
 
 
Institute of pharmacology, MMC  20 
  
Signs and symptoms of the live disease 
13,14 
          Symptoms partly depend on the type and the extent of liver disease. In many cases, 
there may be no symptoms. Signs and symptoms that are common to a number of 
different types of liver disease include Jaundice or yellowing of the skin, Darkened urine, 
Nausea, vomiting, Loss of appetite, Unusual weight loss or weight gain, Diarrhoea, 
Light-coloured stools,Abdominal pain in the upper right part of the stomach, Generalized 
itching, Varicose veins (enlarged blood vessels), Hypoglycaemia (low blood sugar), 
Muscle aches and pains and depression  
Risk factors 
          A numbers of factors increase the risk of developing liver disease, which can lead 
to liver failure. Risk factors include alcoholism, coronary artery disease (due to 
atherosclerosis or hardening of the arteries, or other causes), diabetes, Exposure to 
certain toxins, such as arsenic, Exposure to hepatitis, High triglyceride levels in the 
blood, Long-term treatment with corticosteroids and Obesity. 
 
Some of the drugs currently available in the management of liver disease are, 
Silymarin
15 
          Silymarin is drived from the milk thistle silybum marianum. The milk thistle 
extracts has been shown to reduce lipid peroxidation and inhibit fibrogenesis. The 
compound has been found to be safe, but reportedly has fixed effects. In one study 
examining Silymarin use in alcoholics, mortality was reduced; patient with early stages 
of cirrhosis appeared to benefit. However, in another study in alcoholics, no survival 
benefit could be identified. Silymarin appeared to be safe and is commonly used by 
patients with fibrosing liver diseases. 
Review of Literature 
 
 
Institute of pharmacology, MMC  21 
  
 
Mechanism of action 
          Silymarin hepatoprotective effects are purportedly accomplished via several 
mechanisms; these include: 
 Anti-oxidation 
 Inhibition of lipid peroxidation 
 Stimulation of ribosomal RNA polymerase and subsequent protein synthesis, 
leading to enhanced hepatocyte regeneration 
 Enhanced liver detoxification via inhibition of phase I detoxification 
 Enhanced glucuronidation and protection from glutathione depletion 
 Anti-inflammatory effects, including inhibition of leukotriene and 
prostaglandin synthesis, kupffer cell inhibition, mast cell stabilization, and 
inhibition of neutrophil migration 
 Slowing or even reversing of fibrosis by reduction of the conversion of hepatic 
stellate cells into myofibroblasts 
 Anticarcinogenesis by inhibition of cyclin-dependent kinases and arrest of 
cancer cell growth 
 Silymarin is also found to have immunomodulatory effects on the diseased 
liver 
Clinical application 
          Silymarin has been used in the management of chronic hepatic diseases in humans 
such as primary biliary cirrhosis, biliary disease secondary to cystic fibrosis, non-
alcoholic steatohepatitis, idiopathic chronic hepatitis, autoimmune hepatitis, primary 
sclerosing cholangitis, and alcoholic hepatitis. 
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Polyenylphosphatidylcholine 
          Polyenephosphatidylcholine is a mixture of polyunsaturated phosphatidylcholine, 
extracts from soyabeans. This compound has antioxidant properties and oxidant stress is 
believed to be important in the inflammatory and fibrogenic response to injury, 
particularly in alcoholic liver disease. Because oxidative stress leads to lipid peroxidation 
and lipid peroxidation in injurious at the level of the cell membrane phosphatidylcholine 
has been proposed to be protective of injury to cell membranes, resulting in reduced 
cellular injury and fibrogenesis. 
ANTIOXIDANT AGENTS
10 
          Oxidative stress is thought to play an important role in injury, stellate cell 
activation, and stimulation of extacellular matrix production as described previously. 
Thus a wide variety of antioxidants have received attention as potential antifibrotics. 
 
Vitamins E 
          Vitamins E are a lipid-soluble antioxidant that presumably protects cell 
membranes from oxidative stress, although the precise mechanism by which is unknown. 
 
Other antioxidant 
          Malotilate is another potential cytoprotective agent, perhaps acting via inhibition 
of cytochrome P-450 2E1; on addition, this compound may have anti-inflammatory 
properties. Although malotilate was found to diminish plasma cell and lymphocytic 
infiltrate and piecemeal necrosis in patients with primary biliary cirrhosis, it had no 
significant effect on fibrogenesis.      
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          Another agents used to antagonize oxidative stress is S-adenosylmethionine; this 
compound is important in the synthesis of the antioxidant glutathione. The enzyme 
responsible for its synthesis (methionine adenosyltransferase) is reduced in the injury; 
thus it has been hypothesized that if S-adenosylmethionine was replaced, then injury and 
fibrogenisis might be slowed. 
 
          Propylthiouracil is an antithyroid drug that reacts with some of the oxidized 
species derived from the respiratory burst and thus may be protective in alcoholic liver 
disease, a disease in which an increase in hepatic oxygen consumption may predispose 
the liver to ischemic injury.  
 
CYTOPROTECTIVE AGENTS 
Ursodeoxycholic Acid 
          Ursodeoxycholic acid binds to hepatocyte membranes, where it presumably 
stabilizes them and is thus cytoprotective. Such cytoprotective action theoretically 
reduces inflammation and may in turn have a beneficial effect on fibrogenesis. Although 
the compound has been examined extensively up to date neither experimental data nor 
human studies indicate that ursodeoxycholic acid has a primary antifibrotic effect in the 
liver. 
Mechanism of action 
          It is more hydrophilic and hepatoprotective than the major circulating bile acids in 
humans. The immunomodulatory effects of ursodeoxycholic acid are to involve 
decreased immunoglobulin production by B lymphocytes, decreased interleukin-1 and 
interleukin-2 production by T lymphocytes, decreased expression of hepatocyte cell 
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surface membrane HLA Class 1 molecules and possibly stimulation of the hepatocyte 
glucocorticoid receptor. 
Clinical applications 
          Ursodeoxycholic acid has been used in the management of chronic hepatic 
diseases in humans such as primary biliary cirrhosis, biliary disease secondary to cystic 
fibrosis, non-alcoholic steatohepatitis, idiopathic chronic hepatitis, autoimmune hepatitis, 
primary sclerosing cholangitis, and alcoholic hepatitis. 
 
Adverse effects 
     Diarrhoea, Vomiting  
Penicillamine 
          Penicillamine is a degradation product of penicillin but has no antimicrobial 
activity. It was first isolated in 1953 from the urine of a patient with liver disease who 
was receiving penicillin. 
 
          Penicillamine is a monothiol chelating agent which is used in veterinary medicine 
in the treatment of copper-storage hepatopathy (e.g. Bedlington Terriers), lead toxicity 
and cysteine urolithiasis. It has also been used in the management of rheumatoid arthritis 
and Wilson;s disease. 
Dosage and formulations 
          For management of copper-associated hepatopathy, a dose of 10-15 mg/kg q12h 
p.o is given. 
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Adverse effects 
 GIT adverse effects are common resulting in nausea and vomiting. Smaller doses 
on a more frequent basis may alleviate adverse effects. Aldernatively, the drug 
can be given with food although this will reduce absorption. 
 
Other adverse effects observed infrequently or rarely includes, 
 Fever 
 Lymphadenopathy 
 Skin hypersensitive reaction 
 Immune-complex glomerulonephopathy 
 
Anti-inflammatory compounds
6 
          Many liver diseases such as HCV have an important inflammatory component. 
Inflammation in these disorders typically drives stellate cell activation and fibrogenesis, 
and these diseases in particular have been studied in order to evaluate the efficacy of 
anti-inflammatory drugs. 
 
Cordicosteroids 
          Classic examples of the benefits of steroids include the improvements seen in 
patients with autoimmune hepatitis and alcoholic hepatitis. It could be argued that these 
two diseases are driven largely by inflammation, and thus the anti-inflammatory action 
of steroids serves to treat the underlying process. Not with standing, in patients with 
autoimmune hepatitis who respond to medical treatment (prednisone or equivalent), 
advanced fibrosis and cirrhosis are reversible. Fibrosis may improve in patient with 
alcoholic liver disease who respond to cordicosteroids appear to have antifibrotic effects 
in patients with certain liver disorders. 
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Interleukin-10 
          Interleukin-10 (IL-10) has both anti-inflammatory and immunosuppressive effects. 
IL-10 has been shows to reduce production of proinflammatory cytokines, such as TNF-
α, IL-1, INF-ɣ, and IL-2 from T cell. These cytokines belong to the TH1 family. 
Endogenous IL-10 reduces the intrahepatic inflammatory response, shifts the e cytokine 
milieu towards TH2 predominance, and reduces fibrosis in several in vivo models of 
liver injury.  
TNF inhibitors 
          Because TNF-α amplifies inflammation in many diseases, and because TNF-α is 
up-regulated in liver diseases such as alcoholic hepatitis, an anti- TNF-α compound 
should theoretically reduce inflammation and the stimulus for fibrosis. 
 
          The current available drugs, though useful, are also associated with side effects. 
 
3.2 IMPORTANT OF HERBS IN TREATING LIVER DISORDER 
 
          Herbal medicines are in great demand in the developed world due to their efficacy, 
safety and lesser side effects. Herbal drugs are most widely used than allopathic drugs as 
hepatoprotective because they are inexpensive, have better curable acceptability, better 
compatibility with the human body and minimal side effects. 
          A number of plants and traditional formulations are available for the treatment of 
liver diseases. Around 170 phytoconstituents isolated from 110 plants belonging to 55 
families have been reported to possess hepatoprotective activity
16
.It is estimated that 
about six hundred (600) commercial herbal formulations are used over as 
hepatoprotective drugs. 
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          Amongst the many plants that have hepatoprotective activity, silymarin is widely 
used as a hepatoprotectant around the world. It is a mixture of flavonoid complexes and 
is the active component of milk thistle plant that protects liver and kidney cells from 
toxic effects of drugs, including chemotherapy
17
. Silymarin is composed of a mixture of 
four isometric flavonolignans: silibinin, isosilibinin, silydianin and silychristin. 
Silymarin possesses free radical scavenging ability, it increases antioxidant enzymes 
such as superoxide dismutase (SOD) and catalase and inhibit lipid peroxidation. It is 
reported to offer protection against various chemical hepatotoxins such as CCl4 and 
alcoholic liver.
18 
 
          There are many plants which have not been subjected to scientific evaluation. One 
such plant is Erythrina indica Lam it’s belongs to the family of fabaceae. In this plant the 
leaves have been studied and they are known to possess hepatoprotective activity. The 
leaves contain rich phytoconstituents like flavonoids, isoflavonoids, flavones, coumarins, 
phenols
19,20,21
.
 
The presence of flavonoids has been reported as the reason for their 
hepatoprotective activity. 
 
          The stem bark not been so far subjected to hepatoprotective activity screening. 
Hence the present study was carried out to explore the hepatoprotective efficacy of stem 
bark of Erythrina indica Lam against CCl4 induced hepatotoxicity in rat’s model.  
 
3.5 PHARMACOLOGICAL INVESTIGATION 
          Mujahid M et al., conducted a research study to determine hepatoprotective 
potential of leaves of Erythrina indica (methanolic extract) against anti-tubercular drugs 
induced hepatotoxicity in experimental rats. Hepatoprotective potential assessed by 
evaluating histological examination, biochemical parameters SGOT, SGPT, ALP, 
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bilirubin, total protein, albumin, LDH.  In vivo antioxidant activities such as SOD, CAT, 
GSH and LPO were studied. Histopathology of liver tissue showed that Erythrina indica 
attenuated the hepatocellular necrosis, regeneration and repair of cells toward normal. 
From the result, it was showed the extract had strongly indicated the protective effect of 
Erythrina indica against liver injury which may be attributed to its hepatoprotective 
activity.
22 
 
          A study was conducted by Yashwant Kumar A et al., with different extracts of 
Erythrina indica stem bark to evaluate Hypoglycaemic and anti-diabetic activity in 
normal and alloxan-induced diabetic rats. Effect was assessed by parameters like 
mortality, FBG, insulin levels, blood glucose level, body weight and Oral glucose 
tolerance test. The data showed that the aqueous extracts treatment caused a reduction in 
BGL when compared to the alcoholic extract, indicating the potency of aqueous extract. 
These results indicated that E. indica possesses hypoglycaemic activity on repeated 
administration in alloxan induced diabetic rats.
23 
 
          Kamalraj R et al., conducted a research study to determine the effect of different 
extracts of Erythrina indica on stress induced alteration on lipid profile in rats. Effect 
was assessed by parameters like serum lipid levels (TC) and HDL cholesterol, LDL & 
VLDL cholesterol. In control group stress increased the lipid levels in rats significantly 
except HDL cholesterol. When Erythrina indica treated rat’s serum lipid levels increased 
significantly except HDL cholesterol. This study indicates that various fraction of the 
ethanolic extract of Erythrina indica is effective in attenuating stress induced 
dyslipidemia in rats.
24 
 
Review of Literature 
 
 
Institute of pharmacology, MMC  29 
  
          A study was conducted by Ajay Kumar P et al., with two different extracts of 
Erythrina indica bark to evaluate In-vitro antioxidant and anti-inflammatory activities. 
Standard Methanolic and ethyl acetate extracts of Erythrina indica was tested in vitro for 
its anti-inflammatory activity and antioxidant activity using anti denaturation and 
reducing power methods respectively. The Methanolic extract possesses significant anti-
inflammatory and antioxidant effect where as ethyl acetate extract possesses moderate 
anti-inflammatory and antioxidant activity.
25 
 
          A study was conducted by mohd mujahid et al., with methanolic extract of 
Erythrina indica to evaluate in vitro free radical scavenging activity by using 
1,1diphenyl, 2 picryl hydrazyl assay (DPPH), reducing power and nitric oxide 
scavenging activity. This study indicates that E. indica is a potential source of natural 
antioxidant.
26 
 
          Meena Agarwal et al., conducted a research study to determine antimicrobial 
potential Erythrina indica. The various plant part (root, stem, and leaf) of extracts of E. 
indica were screened for antibacterial activity and antifungal activity against selected test 
microorganisms.  Result indicated that all extracts showed significant antibacterial 
activity against P. funiculosa, F. moniliformae. Among all extracts only stem part of E. 
indica showed antifungal activity against P. funiculosum. From the result, it was reveals 
that extracts of E. indica are showing antimicrobial potential against tested 
microorganism.
27 
 
          Suthar S et al. evaluated to determine analgesic activity of aqueous extract of 
aerial part of Erythrina indica (AEEI) in Rodents. AEEI was evaluated for both 
peripheral and central analgesic activities by acetic acid induced writhing, tail immersion 
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and hot-plate methods. The evaluating parameters are Writhing reflex, Jumping hind paw 
licking response and withdrawn of tail from hot water. From the results AEEI exhibited 
significant analgesic activities on experimental animals as compared to the standard.
28
 
 
          A study was conducted by Jesupillai M et al., to evaluate the anticonvulsant effects 
of different extracts of leaves of Erythrina indica Lam on electrically and chemically 
induced seizures. From the result all the extracts possessed significant (P<0.05) 
anticonvulsant activity. Ethanol extract has been found to have prominent activity when 
compared to other extracts.
29
  
 
          Verma S M et al., conducted the study to evaluate the anti-inflammatory and 
sedative, hypnotic activity of the leaves of Erythrina indica Lam in albino rats in which 
the plants were subjected to successive extraction with methanol. Carragenan induced 
paw oedema model used for study of anti-inflammatory effect and Pentobarbital sodium 
induced sleep method. The extract exhibited significant anti-inflammatory and mild 
sedative activity.
30
 
 
          Vadivel et al., studied the antioxidant potential and Type II diabetes related 
functionality using methanolic extract of Erythrina indica Lam., plant seeds. Ferric 
reducing/antioxidant power assay, β-carotene degradation assay, DPPH assay, 
superoxide radical scavenging assay, starch digestion bioassay and inhibition of α-
amylase and α- glucosidase enzyme activities were performed. From the result 
methanolic extract showed marked antioxidant potential and Type II Diabetes related 
functions.
31
 
 
          A study was conducted by Soniya S et al., with ethanolic extract of Erythrina 
indica leaves to evaluate antihyperlipidemic activity in high fat diet which induced 
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hyperlipidemia in rats. The effect was assessed by parameters like TC, TG, LDL, VLDL 
and HDL levels. Ethanolic extract of Erythrina indica leaf at two dose levels i.e., 
200mg/kg and 400mg/kg for 28 days resulted in the reduction of TC, TG, LDL, VLDL 
and HDL level in the high fat diet which induced hyperlipidemia in rats. From the result, 
Erythrina indica plant was found to possess antihyperlipidemic activity.
32 
 
          Kamalraj R.., conducted a study to evaluate antihyperlipidemic activity of the 
leaves of Erythrina indica Lam in albino rats in which the plants were subjected to 
successive extraction with aqueous solvent using high fat diet induced hyperlipidemia of 
rats model. The effect was assessed by parameters like TC, TG, LDL, VLDL and HDL 
levels. The results are compared to that of standard drug, simvastatin 5mg/kg. So the 
present study supports the earlier claims of the plant in obesity.
33 
 
          A study was conducted by Sakat Sachin S et al., with methanolic extract of 
Erythrina indica Lam leaves to evaluate antiulcer activity in pylorus ligated and 
indomethacin induced ulceration in albino rats. The effect was assessed by parameters 
like total acidity, free acidity, peptic activity and ulcer index. Ulcer index and percentage 
inhibition of ulceration was determined for indomethacin induced ulcer model. From the 
result, the methanol extract of E. indica leaves possessed significant antiulcer properties 
in a dose dependent manner.
34 
 
          Sakat SS et al., studied the Erythrina indica Lam., leaves extracts for antioxidant 
activity. Aqueous and methanol extracts of Erythrina indica leaves were used for in vitro 
methods viz. 1, 1-Diphenyl-2-Picrylhydrazyl, nitric oxide radical scavenging activity, 
and inhibition of lipid peroxidation by thiobarbituric acid reactive substances (TBARS) 
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method on isolated rat liver tissues. From the results, it is concluded that the aqueous and 
methanol extracts of E. indica leaves possesses significant antioxidant activity.
35 
 
          Patil D D et al., demonstrated with aqueous and methanol extracts of Erythrina 
indica root and bark to evaluate diuretic activity in rats. The effect was assessed by 
measuring urine volume, sodium and potassium content and chloride content. From the 
result, aqueous and methanol extracts of Erythrina indica produced significant diuretic 
effect.
36 
          Jesupillai M et al., studied the leaves of Erythrina indica using various extracts of 
ethanol, chloroform and ethyl acetate for its anthelmintic property against Pheritima 
Posthuma. The activity was assessed by the determination of time of paralysis and time 
of death of earth worms. Piperazine citrate (10mg/kg) was included as standard. All the 
three extracts exhibited good anthelmintic activity.
37 
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3.4 PLANT PROFILE 
 Erythrina indica (Lam.,) belongs to the family of fabaceae. 
SYNONYMS 
Erythrina corallodendrum var. orientalis L., 
Erythrina indica Lam. 
Erythrina orientalis (L.,) Merrill 
Tetradapa javanorum Osbeck 
BOTANICAL CLASSIFICATION 
                             Kingdom            :                 Plantae 
                             Division             :                 Magnoliophyta 
                             Class                  :                 Magnoliopsida 
                             Order                 :                  Fabales 
                             Family               :                  Fabaceae 
                             Subfamily          :                  Papilionaceae 
                             Genus                :                  Erythrina 
                             Species              :                  Erythrina indica 
BOTANICAL NAME                      
                         Erythrina indica Lam 
VERNACULAR NAME
38 
English      :         Indian coral tree 
Hindi         :         Pangri, Dadak  
Bengali      :         Palte, Madar 
Malay        :         Dedap 
Tamil        :         Mulu murungu 
Marathi     :         Pangara  
Sanskrit     :        Paribhadra 
Kingdom             
ivision              
lass                   
rder                  
a ily                
ubfa ily           
enus                 
pecies               
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: 
: 
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PLANT PICTURE 
 
Fig.4: Erythrina Indica whole plant and E. Indica stem bark 
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DISTRIBUTION 
          Erythrina indica (Coral tree) which is found in the wild tropics and deciduous 
forests of India.
39 
 
DESCRIPTION 
          Erythrina indica Lam. (Family: Fabaceae), commonly known as 'Indian Coral tree' 
is a medium sized, spiny, deciduous tree with brilliant red blossoms flower, normally 
grows up to 6–9 m height. It is an evergreen forest tree that grows in both acid and 
alkaline soils
40,41,42.Young stems and branches are thickly armed with stout conical 
spines up to 8 mm long, which fall off after 2-4 years; rarely, a few spines persist and are 
retained with the corky bark. Bark smooth and green when young, exfoliating in papery 
flakes, becoming thick, corky and deeply fissured with age. Leaves trifoliate, alternate, 
bright emerald - green, on long petioles 6-15 cm, rachis 5-30 cm long, prickly. Leaf 
petiole and rachis are spiny. Flowers in bright pink to scarlet erect terminal racemes. 
 Fruit a cylindrical torulose pod, green, turning black and wrinkly as they ripen, 
thin-walled and constricted around the seeds. There are 1-8 smooth, oblong, dark red to 
almost black seeds per pod
43, 44
. Fruits are cylindrical torulose pods, containing 1-8 dark 
black coloured seeds. Erythrina comes from the Greek word ‘eruthros’ means red, which 
is colour of its flowers.
45, 46
 
 
PHYTOCONSTITUENTS 
          The plant contains alkaloids, flavonoids, sterols, terpenoids, fatty acids and 
saponins. 
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Bark and leaves 
 Flavonoids such as erytrinin C, 8-prenyl, Indicanin E, isoflavones such as 
genistein, indicanin D and wighteone.  
 Triterpenes such as erythrodiol, oleanlic acid.47  
 Steroidal compounds such as stigmasterol, β, γ and δ-sitosterol.48  
 
Root bark   
 Coumarins such as indicanine A and indicanine B.  
 Flavonoids such as indicanine C and alpinium isoflavone, 4-5-Di-O-Methyl 
isoflavone namely cajanin daidzein
49
 and 8-prenyl diadzein.
50  
Flowers  
 kaempferol.51  
 Flavones, 4-5-7-trihydroxy-3-methoxy-8-c-prenyl, 7-o-beta-D-glucopyranoyl (1-
3) - alpha-7-arabinopyranoside. 
Seed 
 Seed oil shows presence of linoeic acid, lignoceric acid and oleic acid.52 
 Dried seed shows presence of lectin.53 
 
USES 
Leaves 
Rheumatic joints, antidote to strychnine poisoning, irregular menstruation and for 
enhancing milk secretion by lactating mothers
54
, gallstone colic, expectorant, febrifuge, 
and vermifuge
55
, fresh leaves are cooked in coconut milk or goat’s milk and honey and 
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used as a health tonic by lactating women for promoting milk secretion and delay 
premature labour.
56 
Bark 
Fever, malaria, rheumatism, toothache, also for boils, antidote to strychnine 
poisoning, fractures
57,58
, anthelmintic, aphrodisiac, laxative, diuretic, emmenagogue
59
, 
The decoction of the bark is reported to be used orally as anthelmintic, expectorant
60
, 
regulate menstrual flow and irregular menstruation, astringent, collyrium in ophthalmia 
and as antibiliousness agent.
61,62 
Roots   
GIT problems, malaria and burns
63 
and galactagogue.
64 
Shoot   
Anthelmintic, aphrodisiac, laxative, diuretic and emmenagogue.
36,37 
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5. MATERIALS AND METHODS 
 
5.1 Plant collection and identification 
          Fresh stem bark of Erythrina indica Lam was collected from the forest around 
Vellimalai estate, Theni district, Tamilnadu, India in the month of August 2016. It was 
authenticated by Prof. P. Jayaraman, Director, Retd, Professor, Institute of Herbal 
Botany, Presidency College, Chennai-5    
 
5.2 Preparation of plant extract
23 
          The freshly collected stem bark of this plant was shopped and dried. The dried 
material was powder. The powdered plant material (250 g) was extracted by hot 
continuous soxhlet extraction method and the plant material was extracted with Ethanol 
(99.9% v/v), Ethyl acetate and Petroleum ether for four days in a soxhlet apparatus. 
  
          It is a process of continuous extraction method in which the solvent can be 
circulated though the extractor for several time. The vapours from the solvents are taken 
to the condenser and the condensed liquid is returned to the extract for continuous 
extraction. The apparatus consist of body extractor (thimble) attached with side siphon 
tube fixed in lower and attached with distillation flask and the mouth of the extractor is 
fixed to the condenser by the standard joints. 
Procedure 
 Weigh about 250 g dried powdered plant and transferred into a thimble for 
packing. 
 While packing, the content was wetted with Ethanol, Ethyl acetate and 
Petroleum ether respectively and poured until the siphon tube was filled. 
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 A piece of porcelain was added into the round bottom flask to avoid 
bumping effect. 
 After assembling the extractor, the plant material was extracted at about (40-
45ºC), (35-40ºC) and (20-30ºC) temperature respectively until the colour of 
the solution in the siphon tube become pale. 
 The extracts obtained were dried at room temperature and the yield was 
stored in air tight container. 
 
DRUG AND CHEMICALS 
          Ethanol, Ethyl acetate, Petroleum ether, Silymarin, Beta cyclo dextrin,  
 
5.3 PHYTOCHEMICAL ANALYSIS
65 
 
1. TEST FOR ALKALOIDS 
          A small portion of the extract was stired with few drops of dilute hydrochloric acid 
and filtered. The filtrated portion was tested carefully with various alkaloidal reagents 
such as Mayer’s reagent (cream precipitate), Dragendroff’s reagent (orange brown 
precipitate), Hager’s reagent (yellow precipitate), and Wagner’s reagent (reddish brown 
precipitate). 
2. TEST FOR FLAVONOIDS 
Schinado’s test:             To the extract, a few manganesium turnings and few drops of 
concentrated hydrochloric acid were added and boiled for 5 
minutes. The red colour indicates the presence of flavonoids. 
 Sodium hydroxide test:  To the extract in ethanol, 10% sodium hydroxide was added. 
The dark   yellow colorations indicate the presence of 
flavonoids. 
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3. TEST FOR TANNINS AND PHENOLIC COMPOUNDS 
          The extract was dissolved in distilled water. The extract was then divided into 
three parts. A sodium chloride solution (10%) was added to one portion of test’s extract, 
1% gelatin solution to second portion and the gelatin salt reagent to third portion. 
Precipitation with the later reagent or with both the gelatin salt reagent was indicative of 
the presence of tannins. Precipitations of sodium chloride solution indicate a false-
positive test. Positive tests were confirmed by the addition of a few drops of dilute ferric 
chloride (1% ferric chloride) to test extracts, which have black or green coloration. 
          The extract was mixed with lead acetate solution and observed for white 
precipitate. 
 
4. TEST FOR TERPENOIDS 
Noller’s test:           The extract was warmed with tin and thionyl chloride. The pink                
                               coloration indicates the presence of terpenoids. 
 
5. TEST FOR GLYCOSIDES 
Borntrager’s test:    A small amount of extract was hydrolysed with hydrochloric acid 
for few hours on a waterbath and the hydrolysate was extracted 
with benzene. The benzene layer was treated with dilute solution 
and observed for formation of reddish pink color. 
Legal’s test:              The extract was dissolved in pyridine and was made alkaline with 
few drops of 10% sodium hydroxide and freshly prepared sodium 
nitroprusside was added and observed for the formation of blue 
color. 
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6. TEST FOR SAPONINS 
Foam test:              A small amount of extract was extracted with petroleum ether. The 
insoluble residue left after extraction, a few (ml) of water was added 
and shaken vigorously for 15 minutes and was observed for the 
formation of honeycomb forth that persisted for at least 30 minutes. 
7. TEST FOR PROTEIN 
 Biuret test:        The extract is treated with an equal volume of 1% strong NaOH 
following by a few drops of copper (II) sulphate. The formation of 
purple colour indicates the presence of protein. 
 
Million’s test:    Million’s reagent is added to the extract, a white precipitate is produced, 
while heating it turns brick red colour. It indicates the presence of 
protein. 
 
8. TEST FOR MUCILLAGE 
          The extract is treated with aqueous potassium hydroxide; swelling indicates the 
presence of mucillage. 
 
9. TEST FOR CARBOHYDRATES 
Molish’s reagent : To the extract few drops of α-naphthol solution in alcohol, 
con.H2SO4 is added at the side of test tube. The formation of violet 
ring at the junction of two liquids indicates the presence of 
carbohydrates. 
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10. TEST FOR PHYTOSTEROLS 
Libermann-Burchard test: 1 mg of the extract was dissolved in few drops of chloroform, 
3 ml of acedic anhydride and 3 ml of glacial acedic acid. It is 
warmed and cooled under tap water and drops of 
concentrated sulphuric acid were added along the side of the 
test tube. The formation of bluish green colour indicates the 
presence of steroids.  
 
FLAVONOID CONTENT
66,67
  
          Total flavonoid content was measured by the aluminium chloride colorimetric 
assay. An aliquot (1ml) of extracts or standard solutions of quercetin (20, 40, 60, 80 and 
100μg/ml) was added to 10 ml volumetric flask containing 4 ml of distilled water. To the 
flask was added 0.30 ml of 5% NaNO2, after 5min 0.3 ml of 10 % AlCl3 was added. 
After 5min, 2 ml of 1M NaOH was added and the volume was made up to 10 ml with 
distilled water. The solution was mixed and absorbance was measured against the blank 
at 510 nm. The total flavonoid content was expressed as mg quercetin equivalents (QE). 
 
5.4 IN VIVO STUDIES 
Experimental Animals
 
          The present study was conducted after obtained approval from the Institutional 
Animal Ethics Committee, Madras Medical College, Chennai-03. The protocol met the 
requirements of national guidelines of CPCSEA (PROPOSAL NO: 
IAEC/MMC/16/2016) The Wistar rats (150-200g) used for this study were procured 
from, Central Animal House, Madras Medical College, Chennai-03. 
 
Materials & Methods 
 
 
Institute of pharmacology, MMC  44 
 
Quarantine and Acclimatization
68 
          Quarantine is the separation of newly received animals from those already in the 
facility until the health and possibly the microbial status of the newly received animals 
have been determined. The newly procured “Wistar Albino rats” were quarantined for 
the period of one week to minimize the chance of introduction of pathogens into 
established animals and allowed to develop the physiological and nutritional stabilization 
before their use. 
 
Housing 
          The animals are housed in well ventilated animal house which is maintained at a 
constant temperature and relative humidity of 55-65%. The animals are housed in 
spacious polypropylene cage and paddy husk are utilized as bedding materials. 
 
Diet and water 
          The animals are maintained and given on standard pellet diet and purified water. 
The animals are provided with food and water (ad libitum) expect during fasting. The 
bedding materials are changed frequently. 
 
Drug administration 
          Drug is administered by oral gavage using oral feeding tube fixed to a syringe 
needle to administer the required quantity of the drug. 
 
Animal identification 
          All the animal cages used in the study had a proper identification i.e. labels. Each 
animal in cage was marked either on head or body or tail with picric acid for their 
appropriate identification. 
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5.4.1 IN VIVO HEPATOPROTECTIVE EVALUATION  
          The hepatoprotective activity of Erythrina indica Lam., was evaluated in Wistar 
rats. Liver toxicity was induced by intraperitoneal administration of carbon tetrachloride 
(CCl4). The hepatoprotective effect of plant extract was compared with standard drug 
Silymarin. 
 
Drugs and chemicals 
 Carbon tetrachloride  
 Silymarin 
 β - cyclo dextrin (BCD)69 
 
Preparation of drug solutions 
 Carbon tetrachloride was dissolved in olive oil 1:1 
 Extracts was dissolved in 1% BCD 
 Standard drug (Silymarin) was dissolved in distilled water. 
 
Experimental method 
          Carbon tetrachloride induced hepatotoxicity in Wistar albino rats was used as a 
model for screening for hepatoprotective activity. 
 
5.4.1.1 Acute toxicity study (425)
24,70 
          Acute toxicity studies have been already done and it was found to be safe upto 
4000mg/kg p.o. Hence, the doses selected for this study were 400 mg/kg p.o. 
 
Carbon tetrachloride induced hepatotoxicity model
70,71 
          After a week of acclimatization, the rats were divided into seven groups containing 
six animals in each.  
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Table – 2: In Vivo hepatoprotective experimental design 
 
 
S.no 
 
Groups 
 
Treatment schedule 
 
No. of 
animals 
 
1 
Group I 
Normal control 
 
1 ml of 1% BCD p.o. daily for 14 days 
 
6 
 
2 
Group II 
Negative 
control 
1 mg/kg CCl4 in olive oil (1:1), i.p. once in 3 
days for 14 days and received daily a single 
oral dose of BCD  (1ml of 1% w/v) 
 
6 
 
3 
Group III 
Positive 
control 
25 mg/kg of Silymarin p.o. daily for 14 days 
+ (CCl4) 1mg/kg in olive oil (1:1), i.p. once 
in 3days for 14 days 
 
6 
 
 
4 
 
Group IV 
Test group 1 
400mg/kg Ethanolic extract of Erythrina 
indica  in BCD p.o. daily for 14 days + 
(CCl4) 1mg/kg in olive oil (1:1), i.p. once in 
3days for 14 days 
 
6 
 
 
5 
 
Group V 
Test group 2 
400 mg/kg Ethyl acetate extract of Erythrina 
indica in BCD p.o. daily for 14 days + (CCl4) 
1mg/kg in olive oil (1:1), i.p. once in 3days 
for 14 days 
 
6 
 
 
6 
 
Group VI 
Test group 3 
400 mg/kg Petroleum ether extract of 
Erythrina indica in BCD p.o. daily for 14 
days + (CCl4) 1mg/kg in olive oil (1:1), i.p. 
once in 3days for 14 days 
 
6 
 
TOTAL ANIMALS 
 
36 
 
          For all rats, body weight was measured before and after the induction of 
hepatotoxicity (1
th
 and 15
th
 days). On the 15
th
 day, all the animals were mildly 
anesthetized and blood was collected by heart puncture and serum was separated by 
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centrifugation at 2000 rpm for 15-20 minutes at 4
o
C, the serum samples were maintained 
at -80º C, for estimation of biochemical parameters.  
 
          The animals were sacrificed by cervical dislocation method. The liver is removed 
and rinsed with ice cold saline and stored in 10% formalin solution. A part of liver was 
homogenate with phosphate buffer, PH 7.4 using a Teflon homogenizer in ice-cold 
condition. The homogenate of liver as centrifuged at 5000 rpm for 10 min, the 
supernatants solution are taken up for the evaluation of lipid peroxidation (LPO), 
superoxide dismutase (SOD) and glutathione peroxidase (GPx). The other part of liver 
was subjected to Histopathological study. 
 
5.5 BIOCHEMICAL PARAMETERS
 
          The blood samples were collected and allowed to clot and centrifuged at     2000 
rpm for 15-20 minutes using REMI (412 LAG) cooling centrifuge. The serum was kept 
at -80ºC until analyzed. Levels of Alanine Aminotransferase (ALT), Aspartate 
Aminotransferase (AST), Serum Alkaline Phosphate (ALP) Total protein, Albumin and 
Total Bilirubin were determined with an Automated Analyzer (Hitachi 911, Japan). 
 
5.5.1. Estimation of Aspartate Aminotransferase (AST/SGOT)72,73 
          Aspartate Aminotransferase (AST) also referred to as Serum glutamate 
oxaloacetate transferase (SGOT), is an enzyme involved in amino acids metabolism, 
AST is widely distributed in liver, RBC, heart, pancreas and kidney. A high level of AST 
in blood is observed in severe liver disease, kidney disease and lung disease. 
Principle 
  α- Ketoglutarate + L- Aspartate         SGOT        L- Glutamate + Oxaloacetate 
  Oxaloacetate + NADH+H
+                       MDH           
L- Malate + NAD
+    
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          The reagent of NADH consumption is measured photometrically and is directly 
proportional to the AST concentration in the sample. 
 
Reagents 
 L- Aspartate 200 mmol/l 
 Malate dehydrogenase 200 mmol/l 
 α- Ketoglutarate 35 mmol/l 
 NaOH 1.05 mmol/l 
 
Procedure  
          800 µl of L- Aspartate and Malate dehydrogenase and 200 µl of α- Ketoglutarate 
are mixed together and incubated at 37ºC for 2 minutes and 100 µl of sample is added. 
The change in absorbance is measured at 340 nm. 
Calculation  
AST = Abs/min × 1764 (factor) 
 
5.5.2. Estimation of alanine aminotransferase (ALT/SGPT)73 
          Alanine aminotransferase / Serum Glutamate Pyruvate Transferase are an enzyme 
which is involved in amino acids metabolism. 
 
 
Principle 
  α- Ketoglutarate + L- Alanine       SGOT          L- Glutamate + Oxaloacetate 
  Pyruvate +   NADH+H
+                        LDH             
L- Malate + NAD
+    
          The rate of NADH consumption is measured photometrically and is directly 
proportional to the ALT concentration in the sample. 
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Reagents 
 L- Alanine 200 mmol/l 
 Lactate dehydrogenase 200 mmol/l 
 α- Ketoglutarate 35 mmol/l 
 NADH 1.05 mmol/l 
 Tris buffer 80 mmol/l PH 7.5 
 
Procedure  
          800 µl of L- Alanine and Lactate dehydrogenase and 200 µl of α- Ketoglutarate 
are mixed together and incubated at 37ºC for 2 minutes and 100 µl of sample is added. 
The change in absorbance is measured at 340 nm. 
 
Calculation  
ALT = Abs/min × 1764 (factor) 
 
5.5.3. Estimation of alkaline phosphatase (ALP) 74 
Principle 
          When the enzyme incubated with p-nitro phenyl phosphate and Tris buffer (pH 
9.6) in alkaline condition, inorganic phosphate and p-nitro phenol are formed by the 
catalytic action of alkaline phosphatase. Amount of p-nitro phenol liberated by the 
enzyme is measured at 420 nm. 
 
2-aminomethyl-1-propanol + p-nitro phenyl phosphate + H2O 
 
4-nitro phenol + 2-amino-2-methyl-1-propanol phosphate 
 
Requirements 
 p-nitro phenyl phosphate (10 mM) 
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 Tris-HCL pH 9.6 (80 mM) 
 NaOH (0.1 N) 
 
Procedure 
          1ml of p-nitro phenyl phosphate and 1.5 ml of buffer were added with 100 µl of 
homogenate. The mixture was incubated at 37ºC for 30 mins. Then the reaction was 
stopped by addition of 0.1 N NaOH. The absobance of liberated p-nitro phenol was 
measured at 420 nm. 
Calculation  
ALP U/I = ΔA/ 2764 
 
5.5.4. Estimation of total bilirubin (TB)75 
Principle 
          Method of Malloy and Evelyn used to estimate serum bilirubin level. 
     Direct  : (Conjucated) Bilirubin coupled with diazotization Sulfanilic acid, forming 
Azobilirubin, a red-purple coloured product in acidic medium. 
     Indirect  :   (Unconjucated) Bilirubin coupled with diazotized only in the presence of 
its dissolving solvent (Methanol). Indirect fraction and thus represents 
the Total bilirubin concentration. The difference of Total and Direct 
Bilirubin gives Indirect (Unconjucated) Bilirubin. 
          The intensity of red-purple colour so developed above is measured calorimetrically 
and it is proportional to the concentration of the appropriate fraction of Bilirubin. This 
reaction can be represented as: 
                                                                              H
+ 
Bilirubin + Diazotized Sulfanilic Acid                              Azobilirubin 
 
                                                                Red-purple coloured (λ max 540 nm) 
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Reagents 
 Diazo-A, Diazo-B and Diazo blank 
 Methanol 
 Artificial standard 
 Diazo reagent: Just before use, mix 1.0 ml of Diazo-A with 0.03 ml of Diazo-B 
 
Procedure 
          0.1 ml of serum, 0.25 ml of diazo reagent and methanol 1.25 ml were mixed well 
and kept in dark at room temperature for 30 mins and read the optical density (O.D) at 
540 nm against distilled water on a colorimeter with a yellow green filter. 
Calculation 
                                                                                  O.D.T1-O.D.T2 
                               Total Bilirubin =                                                            × 10 
                                                                                 O.D. Standard 
 
 
5.5.5. Estimation of Total Protein (TP) (Biuret Method) 
          Serum content of the soluble proteins, those circulating in extracellular and 
intracellular fluids, has been used as a marker to aid in clinical diagnosis. Serum total 
protein including albumin is mainly involved in the maintenance of osmotic pressure of 
plasma and is used to transport many substances including macromolecules. 
Principle 
          In the biuret reaction, a chelate is formed between the Cu
2+
 ion and the peptide 
bonds of the proteins in alkaline solution to form a violet coloured complex whose 
absorbance is measured photometrically at 540 nm. The intensity of the colour produced 
is proportional to the concentration of the protein in the sample. 
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          Cu
2+
 + Serum protein                                        Copper-protein complex 
                                                                                             (Violet coloured)    
Reagent  
 Total protein reagent (Bilirubin reagent) 
 Protein standard (Standard prepared from bovine serum albumin) 
 Serum sample from animals 
Procedure 
          1ml of biuret reagent which is stored under 2-8ºC and 10 µl of serum 
sample/standard are mixed well and incubated for 5 mins. The intensity of the colour is 
measured at 540 nm. 
 
Calculation  
                                                                              Absorbance of test 
             Total protein in gm/ml    = 
                                                                          Absorbance of standard  
 
5.5.6. Estimation of Albumin (ALB) 
 
Principle 
Bromocresol-Green (BCG) method 
          When albumin binds with bromocresol green in a suitable buffer pH 4.15-4.25, an 
intense blue coloured albumin-BCG complex is formed  
Albumin + BCG (Yellow)                          Albumin-BCG complex (blue) 
 
Reagent 
 Bromocresol green reagent 
 Serum sample from animals 
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Procedure  
          1ml of bromocresol reagent, 1.5 ml of buffer and 0.2 ml serum were mixed and 
kept at room temperature for 10 mins. The absorbance was measured at 630 nm. 
 
5.6 ESTIMATION OF LIPID PEROXIDATION, SUPEROXIDE 
DISMUTASE, GLUTATHIONE PEROXIDASE AND CATALASE 
LEVELS
 77,78 
 
5.6.1. Estimation of lipid peroxidation (LPO)  
          The extent of lipid peroxidation was estimated as evidenced by the formation of 
Thiobarbituric acid reactive substance (TBARS).  
 
TBARS  
          Lipid peroxidation was estimated by the method of Ohkawa et al. (1979). The pink 
colored chromogen formed by the reaction of 2-thiobarbituric acid (TBA) with 
breakdown products of lipid peroxidation was read at 532 nm.  
Reagents  
 
 8.1% sodium dodecyl sulphate (SDS)  
 20 % acetic acid.  
 0.5% 2-thiobarbituric acid (TBA) 
 N-Butanol and pyridine (15:1 v/v)  
 Stock melondialdehyde solution  
 1,1,3,3 - tetramethoxy propone (184 μg/ml)  
 
Procedure  
          To 0.2 ml of liver homogenate, 0.2 ml of 8.1 % SDS, 1.5 ml of 20 % acetic acid, 
(adjusted to pH 2 to 3.5 with NaOH) and 1.5 ml of 0.8 % aqueous solution of TBA were 
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added. The mixture was made up to 4.0 ml with distilled water and then heated in a water 
bath at 95°C for 60 minutes. After cooling with tap water, 1.0 ml of distilled water and 
5.0 ml of a mixture of n-butanol and pyridine were added and shaken vigorously. After 
centrifugation at 4000 g for 10 minutes, the organic layer was removed and its 
absorbance at 532nm was measured. 
 
5.6.2. Assay of superoxide dismutase (SOD): Kakkar et al. (1984).  
          The assay of SOD is based on the inhibition of the formation of NADH- 
phenazinemethosulphate-nitroblue tetrazolium formazon. The color formed at the end of 
the reaction can be extracted into n-butanol layer and measured at 560 nm.  
 
Reagents  
 Sodium pyrophosphate buffer  
 Absolute ethanol  
 n-butanol  
 Phenazine methosulphate (PMS)  
 Nitroblue tetrazolium (NBT)  
 NADH  
 
Procedure  
          0.5ml of tissue homogenate was diluted to 1.0 ml water followed by addition of 
2.5 ml of ethanol and 1.5 ml of chloroform (chilled reagents were added). This mixture 
was shaken for 90 sec at 4º C and then centrifuged. The enzyme activity in the 
supernatant was determined as follows. The assay mixture contained 1.2 mL of sodium 
pyrophosphate buffer, 0.1 mL of phenazine methosulphate and 0.3 mL of nitroblue 
tetrazolium, 0.2mL enzyme preparation and water in a total volume of      2.8 mL. The 
reaction was initiated by the addition of 0.2 mL NADH. The mixture was incubated at 
30C for 90 sec and arrested by the addition of 1ml of glacial acetic acid. The reaction 
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mixture was shaken with 4 mL of n-butanol. The mixture was allowed to stand for 10 
min and centrifuged. The intensity of the chromogen in the n-butanol layer was 
measured at 560 nm in a spectrophotometer (Genesys 10-S, USA). One unit of enzyme 
activity is defined as the amount of enzyme that gave 50% incubation of NBT reduction 
in one minute.  
 
              SOD activity was expressed as Unit/min/mg of protein  
 
Calculation:  
                                           O.D value of control – O.D value of test X100  
     % Inhibition = 
                                                                     O.D of control  
Glutathione peroxidase (GPx) 
 
Principle 
 
                                                 Glutathione Peroxidase 
2 GSH + H2O2                                                                    GSSG + 2 H2O 
                                     
                                                    Glutathione Reductase 
GSSG + ß-NADPH                                                             ß-NADP + 2 GSH 
 
Abbreviations used 
GSH = Glutathione, Reduced Form 
GSSG = Glutathione, Oxidized Form 
β-NADPH = β-Nicotinamide Adenine Dinucleotide Phosphate, Reduced Form 
β -NADP = β -Nicotinamide Adenine Dinucleotide Phosphate, Oxidized Form 
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REAGENTS 
a) 50 mM Sodium Phosphate Buffer with 0.40 mM Ethylenediaminetetraacetic 
Acid   
               (EDTA), pH 7.01 at 25°C. 
b) 1.0 mM Sodium Azide Solution (Buffer w/Azide) 
c) β-Nicotinamide Adenine Dinucleotide Phosphate, Reduced Form (ß-NADPH) 
d) Glutathione Reductase Enzyme Solution (GR) 
e) 200 mM Glutathione, Reduced (GSH) 
f) 10.0 mM Sodium Phosphate Buffer with 1.0 mM Dithiothreitol, pH 7.0 at 
25EC (Buffer w/DTT) 
g) Glutathione Peroxidase Enzyme Solution 
h) 0.042% (w/w) Hydrogen Peroxide (H2O2) (Prepared in Fresh solution) 
 
 
PROCEDURE 
          Prepare a reaction cocktail by pipetting (in millilitres) the following reagents into 
Reagent C (β-NADPH vial): 
Reagent B (Buffer w/Azide)  -   9.20 
Reagent D (GR)    - 0.10 
Reagent E (GSH)    -  0.05 
 
          Mix by inversion and adjust to pH 7.0 at 25°C with 1 M HCl or 1 M NaOH, if 
necessary. Pipette (in millilitres) the following reagents into suitable cuvettes                                                                                
 
                                                                                            Test              Blank 
 
Reaction Cocktail          3.00   3.00 
Reagent F (Buffer w/DTT)                   0.05 
Reagent G (Glutathione Peroxidase)        0.05    
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        Mix by inversion and equilibrate to 25°C. Monitor the A340nm until constant, using 
a suitable thermostated spectrophotometer. Then add: 
                                                                                                   Test              Blank 
Reagent H (H2O2)          0.05    0.05 
 
          Immediately mix by inversion and record the decrease in A340nm for 
approximately 5 minutes. Obtain the A 340nm/minute using the maximum linear rate for 
both the Test and Blank. 
 
CALCULATIONS 
 
                                             (A 340nm/min Test - A340nm/ min Blank)×2× 4.1× Df 
Units/100 µl enzyme =      
                                                                                (6.22) (0.05) 
 
2         =  2 μmoles of GSH produced per μmole of ß-NADPH oxidized 
4.1       =  Total volume (in millilitres) of assay 
Df       =  Dilution factor 
6.22  =  Millimolar extinction coefficient of ß-NADPH at 340 nm 
0.05  =  Volume (in millilitres) of enzyme used 
 
5.6.3. Estimation of catalase (CAT)  
          The activity of Catalase was determined by the method of Sinha (1979). 
Dichromate in acetic acid was converted to perchromic acid and then to chromic acetate, 
when heated in the presence of H2O2. The chromic acetate formed was measured at 620 
nm. The reaction was stopped at different time intervals by the addition of dichromate-
acetic acid mixture and the remaining H2O2 as chromic acetate was determined 
calorimetrically.  
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Reagents  
 Phosphate buffer  
 Hydrogen peroxide  
 Dichromate–acetic acid reagent: 1:3 ratios of 5% potassium dichromate and 
glacial acetic acid.  
 Standard hydrogen peroxide  
 
Procedure  
          0.5ml of tissue homogenate was diluted to 1.0 ml water followed by addition of 
2.5 ml of ethanol and 1.5 ml of chloroform (chilled reagents were added). This mixture 
was shaken for 90 sec at 4º C and then centrifuged. The enzyme activity in the 
supernatant was determined as follows. 0.1 mL of supernatant, 0.9 mL of phosphate 
buffer and 0.4 mL of hydrogen peroxide was added. The reaction was arrested after 60 
seconds by adding 2.0 mL of dichromate-acetic acid mixture. The tubes were kept in a 
boiling water bath for 10 min, cooled and the color developed was read at 620 nm.  
            Catalase activity was expressed as mole of H2O2 consumed/ min/mg of protein. 
 
5.7 HISTOPHATHOLOGICAL STUDIES 
          The liver from the animals was rinsed in ice cold 0.9% saline and was fixed in 
10% formalin embedded in paraffin and cut into 5 µm thick section using a microtome. 
Sections were mounted on class slide using standard techniques. The sections were 
stained with Haematoxylin – Eosin and were examined under a microscope using 400 x 
magnifications and photographed under a light microscope equipped for photography 
(Olympus CK 40).  
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STATISTICAL ANALYSIS
79 
          All the values were expressed as mean ± SEM. The data was statistically analyzed 
by one way ANOVA followed by Dunnet’s test. One way analysis of variance 
(ANOVA) was used to correlate the statistical difference between the variables. P<0.05 
was considered to be significant. Statistical analysis is done by using GraphPad prism. 
 
           
 
 
 
 
 
              
RESULTS 
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6. RESULTS 
6.1. PRELIMINARY PHYTOCHEMICAL ANALYSIS 
Table.3: Preliminary phytochemical analysis of various extract of Erythrina   
               indica Lam. 
 
TEST 
Ethanol 
Extract 
Ethyl acetate 
Extract 
Pet. ether 
Extract 
TEST FOR FLAVONOIDS 
a) Shinado’s test 
b) Sodium hydroxide test 
 
+ 
 
+ 
 
+ 
TEST FOR TANNINS 
With lead acetate 
 
+ 
 
+ 
 
- 
TEST FOR SAPONINS 
Foam test 
 
+ 
 
+ 
 
- 
TEST FOR TERPENOIDS 
With tin and thiol chloride 
 
+ 
 
+ 
 
- 
TEST FOR GLYCOSIDES 
a) Libermann-burchard’s test 
b) Legal’s test 
c) Borntrager’s test 
 
 
- 
 
 
- 
 
 
- 
TEST FOR PHYTOSTEROLS 
Libermann test 
 
+ 
 
+ 
 
  + 
TEST FOR MUCILAGE 
Swelling test 
 
- 
 
- 
 
- 
TEST FOR PROTEIN 
a) Biuret test 
b) Million’s test 
 
+ 
 
+ 
 
+ 
TEST FOR CARBOHYDRATE 
Molish’s test 
 
+ 
 
+ 
 
- 
TEST FOR ALKALOIDS 
a) Dragendroff’s test 
b) Mayer’s test 
c) Hager’s test 
d) Wagner’s test 
 
 
+ 
 
 
+ 
 
 
- 
 
(+ Present)                                  (- absent) 
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6.2. DETERMINATION OF TOTAL FLAVONOID CONTENT 
Table.4:  Standard calibration curve of varying concentration of Quercetin 
 
 
S. No 
 
 
Concentration of 
Quercetin 
(µg/ml) 
 
 
Mean Absorbance 
1 12.5 0.095 
2 25 0.125 
3 50 0.165 
4 100 0.251 
5 200 0.391 
 
Fig.5:  Standard calibration curve of varying concentration of Quercetin 
 
The total flavonoid content present in the extracts was determined using 
aluminium chloride colorimetric method from the calibration curve of standard 
quercetin. The total flavonoid content in the ethanolic extract of Erythrina indica Lam. 
was found to be 19.67±0.333g QE/100g of extract and ethyl acetate extract of Erythrina 
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indica Lam. was 6±0.577g QE/100g of extract. Petroleum ether extract of Erythrina 
indica Lam. was 13.33±0.333g QE/100g of extract. 
 
Fig.6: Total flavonoid content of ethanol ethyl acetate and petroleum ether 
extracts of Erythrina indica Lam. 
 
 
Table.5: Practical yield of Erythrina indica Lam 
Solvent Practical yield in percentage 
ethanol 10.04% w/w 
Ethyl acetate 4.2% w/w 
Petroleum ether 2.6% w/w 
 
 
 
 
 
 
 
 
 
 
EEEI EAEEI PEEEI
0
5
10
15
20
25
T
o
ta
l 
fl
a
v
o
n
o
id
 c
o
n
te
n
t
(g
 Q
E
/1
0
0
g
 o
f 
d
ri
ed
 e
x
tr
a
ct
)
EEEI
EAEEI
PEEEI
Results 
 
Institute of pharmacology, MMC  63 
 
 
6.3. IN VIVO HEPATOPROTECTIVE ACTIVITY 
 
6.3.1. Body weight  
          The body weight of the animals was determined on 1
st
 and 15
th
 day of the study 
period and these are tabulated in Table-6 and Figure. 7 
 
Table – 6: Body weight of the animals in the various groups 
 
 
GROUPS 
 
 
TREATMENT 
ANIMAL BODY WEIGHT IN gms 
 
1
st
 day 
 
15
th
 day 
I Control 164±3.43 189±2.96 
II Disease control 157±2.31 145±2.73 
III Silymarin (25 mg/kg) 164.7±2.94 161.3±3.18 
 
 
IV 
Ethanolic Erythrina 
indica Lam 
(400 mg/kg ) 
 
166.7±2.46 
 
161±2.21 
 
 
V 
Ethyl acetate extract of 
Erythrina indica Lam 
(400 mg/kg) 
 
 
162.3±2.36 
 
 
152±1.95 
 
 
VI 
Pet. ether extract of 
Erythrina indica Lam 
(400 mg/kg) 
 
163.3±3.82 
 
151.8±2.75 
 
Values are expressed by Mean ± SEM 
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Fig. 7: Body weight of animals in the various groups 
 
 
          It is seen from the data that in the CCl4 treated group there was a slight decrease in 
body weight on the 15
th
 day. In the Silymarin and extracts of Erythrina indica Lam 
treated group shows the reduction in the body weight was lesser than that of CCl4 treated 
group. 
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6.4. BIOCHEMICAL ESTIMATION 
 
6.4.1. Aspartate Aminotransferase (AST) evaluations 
          The AST level of the animals treated with CCl4 alone and those that were given 
CCl4 and Silymarin/ Extracts of Erythrina indica Lam were estimated on Day 15. They 
are tabulated in Table-7 and Figure. 8 
 
Table – 7: Aspartate Aminotransferase levels  
 
GROUP 
 
TREATMENT 
 
AST 
(U/ml) 
 
I 
 
Control 
 
207±3.57
*** 
 
II 
 
Disease control 
 
554±5.96
*** 
 
III 
 
Silymarin (25 mg/kg) 
 
314.7±4.43
*** 
 
IV 
Ethanolic Erythrina indica Lam 
(400 mg/kg ) 
 
327.3±4.43
*** 
 
 
V 
Ethyl acetate extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
 
464.7±4.55
*** 
 
VI 
Pet. ether extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
354±2.75
*** 
 
The value are expressed as Mean ± SEM (n=6) 
***
P<0.001 compared to control group 
###
P<0.001 compared to disease control group 
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Fig. 8: Aspartate Aminotransferase levels 
 
 
         In the Table-7 and Fig.8: It was seen that AST level 554±5.96 had increased 
significantly in animals which were given CCl4 as compared to normal group 207±3.57. 
Treatment with Silymarin showed a significant decrease in the level of AST 314.7±4.43 
as compare to the disease control. The extracts of Erythrina indica Lam treated groups of 
animals also showed a significant decrease in the level of AST 327.3±4.43, 464.7±4.55 
and 354±2.75 respectively. The reduction was more in the group treated with the 
ethanolic extracts of Erythrina indica 327.3±4.43, when compare to other extracts 
treated groups. 
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6.4.2. Alanine aminotransferase (ALT) evaluation 
          The ALT level of the animals treated with CCl4 alone and those that were given 
CCl4 and Silymarin/ extracts of Erythrina indica Lam were estimated on day 15. They 
are tabulated in Table-8 and Figure. 9 
 
Table – 8: Alanine aminotransferase levels 
 
 
GROUP 
 
TREATMENT 
 
ALT 
(U/ml) 
 
I 
 
Control 
 
63.83±1.38
*** 
 
II 
 
Disease control 
 
169.1±2.69
*** 
 
III 
 
Silymarin (25 mg/kg) 
 
81.13±0.85
*** 
 
IV 
Ethanolic Erythrina indica 
Lam 
(400 mg/kg ) 
 
90.16±1.14
*** 
 
 
V 
Ethyl acetate extract of 
Erythrina indica Lam 
(400 mg/kg) 
 
 
137.4±2.89
*** 
 
VI 
Pet. ether extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
103.2±1.82
*** 
 
The value are expressed as Mean ± SEM (n=6) 
***
P<0.001 compared to control group 
###
P<0.001 compared to disease control group 
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Fig.9:  Alanine aminotransferase levels 
 
 
       In the Table-8 and Fig.9: It was seen that ALT level 169.1±2.69 had increased 
significantly in animals which were given CCl4 as compared to normal group 
63.83±1.38. Treatment with Silymarin showed a significant decrease in the level of ALT 
81.13±0.85 as compare to the disease control. The extracts of Erythrina indica Lam 
treated groups of animals also showed a significant decrease in the level of ALT 
90.16±1.14, 137.4±2.89 and 103.2±1.82 respectively. The reduction was more in the 
group treated with the Ethanolic extracts of Erythrina indica 90.16±1.14, when compare 
to other extracts treated groups. 
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6.4.3. Alkaline phosphatase (ALP) evaluation 
          The ALP level of the animals treated with CCl4 alone and those that were given 
CCl4 and Silymarin/ extracts of Erythrina indica Lam were estimated on day 15. They 
are tabulated in Table-9 and Figure. 10 
 
Table – 9: Alkaline phosphatase levels 
 
GROUP 
 
TREATMENT 
 
ALP 
(U/ml) 
 
I 
 
Control 
 
228.2±4.32
*** 
 
II 
 
Disease control 
 
405.9±6.76
*** 
 
III 
 
Silymarin (25 mg/kg) 
 
242.8±3.18
*** 
 
IV 
Ethanolic Erythrina indica Lam 
(400 mg/kg ) 
 
286.9±2.41
*** 
 
 
V 
Ethyl acetate extract of 
Erythrina indica Lam 
(400 mg/kg) 
 
 
377.4±5.75
# 
 
 
VI 
Pet. ether extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
308.4±4.002
*** 
 
The value are expressed as Mean ± SEM (n=6) 
***
P<0.001 compared to control group 
#
P<0.001 compared to disease control group 
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Fig.10: Alkaline Phosphatase levels 
 
 
         In the Table-9 and Fig.10: It was seen that ALP level 405.9±6.76 had increased 
significantly in animals which were given CCl4 as compared to normal group 
228.2±4.32. Treatment with Silymarin showed a significant decrease in the level of ALP 
242.8±3.18 as compare to the disease control. The extracts of Erythrina indica Lam 
treated groups of animals also showed a significant decrease in the level of ALP 
286.9±2.41, 377.4±5.75 and 308.4±4.002 respectively. The reduction was more in the 
group treated with the Ethanolic extracts of Erythrina indica 286.9±2.41, when compare 
to other extracts treated groups.
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6.4.4. Total bilirubin (TB) evaluation 
          The Total Bilirubin level of the animals treated with CCl4 alone and those that 
were given CCl4 and Silymarin/ extracts of Erythrina indica Lam were estimated on day 
15. They are tabulated in Table-10 and Figure. 11 
 
Table – 10: Total bilirubin levels 
 
GROUP 
 
TREATMENT 
 
TB 
 (mg/dl) 
 
I 
 
Control 
 
1.68±0.17
*** 
 
II 
 
Disease control 
 
14.12±0.29
*** 
 
III 
 
Silymarin (25 mg/kg) 
  
2.68±0.30
*** 
 
IV 
Ethanolic Erythrina indica Lam 
(400 mg/kg ) 
 
4.49±0.23
*** 
 
 
V 
Ethyl acetate extract of 
Erythrina indica Lam 
(400 mg/kg) 
 
 
11.47±0.32
## 
 
VI 
Pet. ether extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
7.39±0.32
*** 
 
The value are expressed as Mean ± SEM (n=6) 
***
P<0.001 compared to control group 
##
P<0.001 compared to disease control group 
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Figure. 11: Total bilirubin levels 
 
 
In the Table-10 and Fig.11:  It was seen that Total Bilirubin level 14.12±0.29 
had increased significantly in animals which were given CCl4 as compared to normal 
group 1.68±0.17. Treatment with Silymarin showed a significant decrease in the level of 
Total Bilirubin 2.68±0.30 as compare to the disease control. The extracts of Erythrina 
indica Lam treated groups of animals also showed a significant decrease in the level of 
Total Bilirubin 4.49±0.23, 11.47±0.32 and 7.39±0.32 respectively. The reduction was 
more in the group treated with the Ethanolic extracts of Erythrina indica, when compare 
to other extracts treated groups 4.49±0.23. 
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6.4.5. Total Protein (TP) evaluation 
          The Total Protein level of the animals treated with CCl4 alone and those that were 
given CCl4 and Silymarin/ extracts of Erythrina indica Lam were estimated on day 15. 
They are tabulated in Table-11 and Figure. 12 
 
Table – 11: Total Protein levels 
 
GROUP 
 
TREATMENT 
 
TP 
(g/dl) 
 
I 
 
Control 
 
8.20±0.06
*** 
 
II 
 
Disease control 
 
5.73±0.12
*** 
 
III 
 
Silymarin (25 mg/kg) 
 
7.85±0.08
*** 
 
IV 
Ethanolic Erythrina indica Lam 
(400 mg/kg ) 
 
7.46±0.1
*** 
 
 
V 
Ethyl acetate extract of 
Erythrina indica Lam 
(400 mg/kg) 
 
 
6.42±0.11
# 
 
VI 
Pet. ether extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
6.97±0.16
# 
 
The value are expressed as Mean ± SEM (n=6) 
***
P<0.001 compared to control group 
#
P<0.001 compared to disease control group 
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Fig.12: Total Protein levels 
 
 
          In the Table-11 and Fig.12: It was seen that Total Protein level 5.73±0.12 had 
decreased significantly in animals which were given CCl4 as compared to normal group 
8.20±0.06. Treatment with Silymarin showed a significant increase in the level of Total 
Protein 7.85±0.08 as compare to the disease control. The extracts of Erythrina indica 
Lam treated groups of animals also showed a significant increase in the level of Total 
Protein 7.46±0.1, 6.42±0.11 and 6.97±0.16 respectively. The elevation was more in the 
group treated with the Ethanolic extracts of Erythrina indica 7.46±0.1, when compare to 
other extracts treated groups. 
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6.4.6. Albumin (ALB) evaluation 
          The Albumin level of the animals treated with CCl4 alone and those that were 
given CCl4 and Silymarin/ extracts of Erythrina indica Lam were estimated on day 15. 
They are tabulated in Table-12 and Figure. 13 
 
Table – 12: Albumin levels 
 
GROUP 
 
TREATMENT 
 
Albumin 
(g/dl) 
 
I 
 
Control 
 
3.67±0.02
*** 
 
II 
 
Disease control 
 
1.34±0.01
*** 
 
III 
 
Silymarin (25 mg/kg) 
 
3.38±0.04
*** 
 
IV 
Ethanolic Erythrina indica Lam 
(400 mg/kg ) 
 
2.99±0.13
*** 
 
 
V 
Ethyl acetate extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
 
1.57±0.06
# 
 
VI 
Pet. ether extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
2.33±0.07
*** 
 
The value are expressed as Mean ± SEM (n=6) 
***
P<0.001 compared to control group 
#
P<0.001 compared to disease control group 
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Fig.13: Albumin levels 
 
 
          In the Table-12 and Fig.13: It was seen that albumin level 1.34±0.01 had 
decreased significantly in animals which were given CCl4 as compared to normal group 
3.67±0.02. Treatment with Silymarin showed a significant increase in the level of 
albumin 3.38±0.04 as compare to the disease control. The extracts of Erythrina indica 
Lam treated groups of animals also showed a significant increase in the level of albumin 
2.99±0.13, 1.57±0.06 and 2.33±0.07 respectively. The elevation was more in the group 
treated with the ethanolic extract of Erythrina indica 2.99±0.13, when compare to other 
extracts treated groups. 
 
 
 
 
 
 
 
 
 
 
control CCl4 Silymarin+CCl4 EEEI+CCl4 EAEEI+CCl4 PEEEI+CCl4
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
A
L
B
 g
/d
l
Results 
 
Institute of pharmacology, MMC  77 
 
 
6.5. ESTIMATION OF ANTIOXIDANT ENZYMES LEVELS 
6.5.1. Lipid peroxidation (LPO) 
          Lipid peroxidase enzyme level of the animals treated with CCl4 alone and those 
that were given CCl4 and Silymarin/ extracts of Erythrina indica Lam were estimated in 
liver homogenized solution on Day 15. They are tabulated in Table-13 and Fig. 14 
 
Table – 13: Lipid peroxidation levels 
 
GROUP 
 
TREATMENT 
 
LPO 
(moles/100mg/protein) 
 
I 
 
Control 
 
2.29±0.04
 
 
II 
 
Disease control 
 
7.61±0.07
*** 
 
III 
 
Silymarin (25 mg/kg) 
  
3.69±0.06
*** 
 
IV 
Ethanolic Erythrina indica Lam 
(400 mg/kg ) 
 
4.34±0.06
*** 
 
 
V 
Ethyl acetate extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
 
6.98±0.07
## 
 
VI 
Pet. ether extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
5.85±0.17
## 
 
The value are expressed as Mean ± SEM (n=6) 
***
P<0.001 compared to control group 
##
P<0.001 compared to disease control group 
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Fig.14: Lipid peroxidation levels 
 
         In the Table-13 and Fig.14: It was seen that the LPO level 7.61±0.07 had increased 
significantly in animals which were given CCl4  as compared to normal group 2.29±0.04. 
Treatment with Silymarin showed a significant decrease in the level of LPO 3.69±0.06 as 
compare to the disease control. The extracts Erythrina indica Lam treated groups of the 
animals also showed a significant decrease in the level of LPO 4.34±0.06, 6.98±0.07 and 
5.85±0.17 respectively. The reduction was more in the group treated with the Ethanolic 
extracts of Erythrina indica 4.34±0.06, when compare to other extracts treated groups. 
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6.5.2. Superoxide dismutase (SOD) 
          Superoxide dismutase enzyme level of the animals treated with CCl4 alone and 
those that were given CCl4 and Silymarin/ extracts of Erythrina indica Lam were 
estimated in liver homogenized solution on Day 15. They are tabulated in Table-14 and 
Fig. 15 
 
Table – 14: Superoxide dismutase levels 
 
GROUP 
 
TREATMENT 
 
SOD 
(U mg
-1
 of protein) 
 
I 
 
Control 
 
12.6±0.58
*** 
 
II 
 
Disease control 
 
5.22±0.16
*** 
 
III 
 
Silymarin (25 mg/kg) 
  
8.88±0.21
*** 
 
IV 
Ethanolic Erythrina indica Lam 
(400 mg/kg ) 
 
7.79±0.08
*** 
 
 
V 
Ethyl acetate extract of 
Erythrina indica Lam 
(400 mg/kg) 
 
 
6.40±0.1
## 
 
VI 
Pet. ether extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
7.26±0.14
*** 
 
The value are expressed as Mean ± SEM (n=6) 
***
P<0.001 compared to control group 
##
P<0.001 compared to disease control group 
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Fig.15: Superoxide dismutase levels 
 
 
          In the Table-13 and Fig.15: It was seen that superoxide dismutase enzyme level 
5.22±0.16 had decreased significantly in animals which were given CCl4 as compared to 
normal group 12.6±0.58. Treatment with Silymarin showed a significant increase in the 
level of superoxide dismutase 8.88±0.21 as compare to the disease control. The extracts 
of Erythrina indica Lam treated groups of animals also showed a significant increase in 
the level of superoxide dismutase 7.79±0.08, 6.40±0.1 and 7.26±0.14 respectively. The 
elevation was more in the group treated with the ethanolic extracts of Erythrina indica 
7.79±0.08, when compare to other extracts treated groups. 
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6.5.3. Glutathione peroxidase (GPx) 
          Glutathione peroxidase enzyme level of the animals treated with CCl4 alone and 
those that were given CCl4 and Silymarin/ extracts of Erythrina indica Lam were 
estimated in liver homogenized solution on Day 15. They are tabulated in Table-15and 
Fig.16 
 
Table –15: Glutathione peroxidase levels 
 
GROUP 
 
TREATMENT 
 
GPx 
(nmol NADPH min
-1 
mg
-1 
of protein) 
 
I 
 
Control 
 
167.5±0.83
*** 
 
II 
 
Disease control 
 
79.1±0.81
*** 
 
III 
 
Silymarin (25 mg/kg) 
  
145.6±0.91
*** 
 
IV Ethanolic Erythrina indica Lam 
(400 mg/kg ) 
 
 
135.2±0.69
*** 
 
 
V 
Ethyl acetate extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
 
 
93.85±0.50
*** 
 
VI Pet. ether extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
 
104.6±1.64
*** 
 
The value are expressed as Mean ± SEM (n=6) 
***
P<0.001 compared to control group 
###
P<0.001 compared to disease control group 
 
 
 
 
Results 
 
Institute of pharmacology, MMC  82 
 
 
 
Fig.16: Glutathione peroxidase levels 
 
 
          In the Table-15 and Figure.16: It was seen that Glutathione peroxidase enzyme 
level 79.1±0.91 had decreased significantly in animals which were given CCl4 as 
compared to normal group 167.5±0.83. Treatment with Silymarin showed a significant 
increase in the level of Glutathione peroxidase 145.6±0.91 as compare to the disease 
control. The extracts of Erythrina indica Lam treated groups of animals also showed a 
significant increase in the level of Glutathione peroxidase 135.2±0.69, 93.85±0.50 and 
104.6±1.64 respectively. The elevation was more in the group treated with the Ethanolic 
extracts of Erythrina indica, when compare to other extracts treated groups 135.2±0.69. 
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6.5.4. Catalase (CAT) 
          Catalase enzyme level of the animals treated with CCl4 alone and those that were 
given CCl4 and Silymarin/ extracts of Erythrina indica Lam were estimated in liver 
homogenized solution on Day 15. They are tabulated in Table-16 and Fig.17 
 
Table – 16: Catalase levels 
 
 
GROUP 
 
TREATMENT 
 
CATALASE 
(nmol min
-1 
mg
-1 
of 
protein) 
 
I 
 
Control 
 
489.2±2.75
*** 
 
II 
 
Disease control 
 
213.6±0.99
*** 
 
III 
 
Silymarin (25 mg/kg) 
  
363.1±0.54
*** 
 
IV 
Ethanolic Erythrina indica 
Lam 
(400 mg/kg ) 
 
352.8±0.76
*** 
 
 
V 
Ethyl acetate extract of 
Erythrina indica Lam 
(400 mg/kg) 
 
 
253.6±2.38
*** 
 
VI 
Pet. ether extract of Erythrina 
indica Lam 
(400 mg/kg) 
 
286±1.58
*** 
 
The value are expressed as Mean ± SEM (n=6) 
***
P<0.001 compared to control group 
###
P<0.001 compared to disease control group 
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Fig.17: Catalase levels 
 
          In the Table-16 and Fig.17: It was seen that CAT enzyme level 213.6±0.09 had 
decreased significantly in animals which were given CCl4 as compared to normal group 
489.2±2.75. Treatment with Silymarin showed a significant increase in the level of CAT 
363.1±0.54 as compare to the disease control. The extracts of Erythrina indica Lam 
treated groups of animals also showed a significant increase in the level of CAT 
352.8±0.76, 253.6±2.38 and 286±1.58 respectively. The elevation was more in the group 
treated with the ethanolic extracts of Erythrina indica, when compare to other extracts 
treated groups 352.8±0.76. 
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6.6. HISTOPATHOLOGICAL STUDY 
 A part liver tissue subjected to histopathological evaluation. 
 
Fig. 18: Histopathological studies of liver 
 
                                    
                1)  Normal control                                                  2) CCl4 treated 
                       
    3) CCl4 + Silymarin 25 mg/kg                            4) CCl4 + EEEI 400 mg/kg 
                            
   5) CCl4 + EAEEI 400 mg/kg                             6) CCl4 + PEEEI 400 mg/kg  
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1. In control group, Liver section showing normal histological appearance.  
2. CCl4 induced group of Liver section showed diffuse areas of vacuolar 
degeneration, lobular inflammation, portal to portal fibrosis and centrilobular 
necrosis with mononuclear cell infiltration.  
3. Liver section, standard drug silymarin treated group was showing mild hepatocyte 
vacuolation.  
4. Liver section of CCl4 along with ethanolic extract of E.indica 400 mg/kg: treated 
group was showing mild vacuolar degeneration and mild hepatocyte swelling.  
5. Section of CCl4 along with ethyl acetate extract of E.indica 400 mg/kg treated 
group has shown vacuolar degeneration, lymphocyte present in portal tract and 
mononuclear cell infiltration in parenchyma and portal areas. 
6. Liver section of CCl4 along with pet ether extract of E.indica 400 mg/kg treated 
group has shown mild vacuolar degeneration and mild hepatocyte swelling.  
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7. DISCUSSION 
 
          Liver is an important organ involved in metabolism of many xenobiotics. It 
removes toxins from the body. It is also exposed to several drugs and xenobiotics which 
cause hepatic damage. In the present study hepatoprotective activity on the various 
extracts of stem bark of Erythrina indica Lam was evaluated. 
         The powdered plant material was extracted by hot continuous soxhlet extraction 
method and the plant material was extracted with Ethanol (99.9% v/v), Ethyl acetate and 
Petroleum ether for four days in a soxhlet apparatus. The practical yield of ethanolic 
extract showed 10.04% w/w, ethyl acetate extract showed 4.2% w/w and petroleum ether 
extract showed 2.6% w/w.  
In phytochemical evaluation of ethanolic extract of stem bark of Erythrina indica 
Lam showed the presence of flavonoids, tannins, saponins, terpenoids, phytosterol, 
protein, carbohydrate and alkaloids. Ethyl acetate extract of stem bark of Erythrina 
indica Lam showed the presence of flavonoids, tannins, saponins, terpenoids, 
phytosterol, protein, carbohydrate and alkaloids. Petroleum ether extract of stem bark of 
Erythrina indica Lam showed the presence of flavonoids, phytosterol and protein. 
          It was seen that ethanolic extract of stem bark of Erythrina indica Lam 
showed increased total flavonoid content when compared to other extracts. The observed 
in vivo antioxidant and hepatoprotective activity for this extract therefore may be due to 
the presence of flavonoids
80,81
. The acute toxicity test suggested that the crude extracts of 
the plant was non-toxic to rat upto the dose 4000 mg/ kg. 
          CCl4- induced hepatic injury is an experimental model widely used for the 
screening of hepatoprotective drugs. CCl4 undergoes a biotransformation by hepatic 
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microsomal cytochrome P-450 to produce trichloromethyl free radicals. This hepatotoxic 
metabolite can react with protein and lipid in the membrane of cells or organelles leading 
to necrosis of hepatocytes. As a result of hepatic injury, permeability of the cell 
membrane is altered causing the cytosolic transaminase (ALT, AST), in the circulation. 
Hence evaluation of AST and ALT are definite indicators of hepatoprotective activity. 
The rise in the serum levels of ALP, AST, ALT and bilirubin as observed in the present 
study could be attributed to the damaged structural integrity of the liver. Liver damage is 
also associated with elevated levels of ALT, and Bilirubin. It is also associated with 
decrease in levels of Total Protein and Albumin.
82 
          It was seen that AST, ALT, ALP and bilirubin levels had increased significantly in 
animals which were given CCl4 as compared to normal group. Treatment with Silymarin 
showed a significant decrease in the level of AST, ALT, ALP and bilirubin. The extracts 
of Erythrina indica Lam treated groups of animals also showed a significant decrease in 
the level of AST, ALT, ALP and bilirubin. The reduction was more in the group treated 
with the Ethanolic extracts of Erythrina indica, when compare to other extracts treated 
groups.  
          Total Protein, Albumin levels had decreased significantly in animals which were 
given CCl4 as compared to normal group. Treatment with Silymarin showed a significant 
increase in the level of Total Protein, Albumin. The extracts of Erythrina indica Lam 
treated groups of animals also showed a significant increase in the level of Total Protein, 
Albumin. The elevation was more in the group treated with the ethanolic extracts of 
Erythrina indica, when compare to other extracts treated groups. 
          The administration of various extracts of stem bark of Erythrina indica Lam 
showed improvement in the biochemical parameters profile of the animals. The effect 
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was seen with ethanolic extract of stem bark of E. indica is almost equal to that of the 
standard drug Silymarin. These evaluation studies confirm the hepatoprotective potential 
of various extracts of stem bark of Erythrina indica Lam. 
          It has been hypothesized that one of the principle causes of CCl4- induced liver 
injury is formation of lipid peroxidases by free radical derivatives of CCl4 (CCl3
-
). Thus, 
the antioxidant activity or the inhibition of the generation of free radicals is important in 
the protection against CCl4- induced hepatotoxicity. 
          Lipid peroxidation has been implicated in the pathogenesis of hepatic injury by 
compounds like CCl4 and is responsible for the cell membrane alteration. In the present 
study, elevated level of LPO observed in CCl4 administered rats indicated excessive 
formation of free radicals and activation of LPO system resulting in hepatic damage
81
. It 
was seen that the LPO levels had increased significantly in animals which were given 
CCl4 as compared to normal group. Treatment with Silymarin showed a significant 
decrease in the level of LPO. The various extracts of stem bark of Erythrina indica Lam 
treated groups of the animals also showed a significant decrease in the levels of LPO. 
The reduction was more in the group treated with the ethanolic extracts of Erythrina 
indica, when compare to other extracts treated groups. Hence, it is possible that the 
mechanism of hepatoprotection of Erythrina indica Lam might be due to its antioxidant 
action.  
          The body has an effective defense mechanism to prevent and neutralize the free 
radical-induced damage. This is accomplished by a set of endogenous antioxidant 
enzymes such as SOD, Glutathione peroxidase and Catalase. SOD has been reported as 
one of the most important enzyme in the enzymatic antioxidant defense system. It 
scavenges the superoxide anion to form hydrogen peroxide and thus diminishing the 
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toxic effect caused by this radical. Decrease in enzymatic activity of superoxide 
dismutase (SOD) is a sensitive index in hepatocellular damage and is the most sensitive 
enzymatic index in liver injury
83
. It was seen that Superoxide dismutase enzyme levels 
had decreased significantly in animals which were given CCl4 as compared to normal 
group. Treatment with Silymarin showed a significant increase in the level of Superoxide 
dismutase. The various extracts of stem bark of Erythrina indica Lam causes a 
significant increase in hepatic SOD level indicating a reduction of reactive free radical 
induced oxidative damage to liver. The elevation was more in the group treated with the 
ethanolic extracts of Erythrina indica, when compare to other extracts treated groups. 
          Glutathione is one of the most abundant tripeptide, non-enzymatic biological 
antioxidant present in the liver. The biochemical function of GPx is to reduce lipid 
hydroperoxides to their corresponding alcohols and to reduce free hydrogen peroxide to 
water
84,85
. It was seen that Glutathione peroxidase enzyme levels had decreased 
significantly in animals which were given CCl4 as compared to normal group. Treatment 
with Silymarin showed a significant increase in the levels of Glutathione peroxidase. The 
various extracts of stem bark of Erythrina indica Lam causes a significant increase in 
hepatic GPx level indicating a reduction of reactive free radical induced oxidative 
damage to liver. The elevation was more in the group treated with the ethanolic extracts 
of Erythrina indica, when compare to other extracts treated groups. 
          Catalase (CAT) is an enzymatic antioxidant widely distributed in all animal 
tissues, and the highest activity is found in the red cells and liver. It catalyzes the 
decomposition of hydrogen peroxide to water and oxygen. It is a very important enzyme 
in protecting the cell from oxidative damage by reactive oxygen species (ROS) and 
protects the tissues from highly reactive hydroxyl radicals
83
. Therefore reduction in the 
level of CAT may result in a number of deleterious effects due to the assimilation of 
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superoxide radical and hydrogen peroxide
85,86
. It was seen that catalase enzyme levels 
had decreased significantly in animals which were given CCl4 as compared to normal 
group. Treatment with Silymarin showed a significant increase in the levels of catalase. 
The various extracts of stem bark of Erythrina indica Lam causes a significant increase 
in hepatic Catalase level indicating a reduction of reactive free radical induced oxidative 
damage to liver. The elevation was more in the group treated with the ethanolic extracts 
of Erythrina indica, when compare to other extracts treated groups. 
 From the control group, Liver section showing normal histological appearance. 
CCl4 induced group of Liver section showed diffuse areas of vacuolar degeneration, 
lobular inflammation, portal to portal fibrosis and centrilobular necrosis with 
mononuclear cell infiltration. The liver section of standard drug silymarin treated group 
was showing mild hepatocyte vacuolation. The liver section of CCl4 along with ethanolic 
extract of E.indica 400 mg/kg: treated group was showing mild vacuolar degeneration 
and mild hepatocyte swelling. The liver section of CCl4 along with ethyl acetate extract 
of E.indica 400 mg/kg treated group has shown vacuolar degeneration, lymphocyte 
present in portal tract and mononuclear cell infiltration in parenchyma and portal areas. 
The liver section of CCl4 along with pet ether extract of E.indica 400 mg/kg treated 
group has shown mild vacuolar degeneration and mild hepatocyte swelling.  
 
          Histopathological liver sections also revealed that the hepatic architecture was 
altered by hepatotoxin in Carbon tetrachloride group, whereas in the liver sections of the 
rat treated with the various stem bark extracts of Erythrina indica Lam and intoxicated 
with CCl4, the hepatic architecture was not altered and was comparable with the standard 
drug Silymarin. The histopathological study confirms the significant hepatoprotective 
effect of ethanolic extract of stem bark of Erythrina indica Lam. 
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8. CONCLUSION 
            From the study it is concluded that 
 
 The different extracts of the stem bark of Erythrina indica Lam possessed 
promising hepatoprotective activity against CCl4 induced hepatic damage. 
The hepatoprotective activity of Erythrina indica is found out to be more 
in ethanolic extract.  
 
 The activity could be due to the improvement in the antioxidant enzyme 
level and a decrease in free radical levels. The presence of 
phytochemicals such as flavonoids has been shown to be responsible for 
hepatoprotective activity. 
  
 Further studies can be carried out in the future to elucidate the mechanism 
of action of the ethanolic extract of stem bark of Erythrina indica Lam, 
which may then be followed and clinical studies to establish its efficacy in 
humans. 
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